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After budding from infected cells, Human Immunodeficiency Virus type 1 (HIV-1) 
undergoes a maturation process that is required for viral infectivity. In the immature state, 
the major structural protein of viral particles, Gag, forms a thick protein shell underneath 
the viral membrane. During maturation, Gag is cleaved by HIV-1 protease and the 
resulting mature particles have a much thinner membrane-bound protein layer 
surrounding a conical core (capsid), which is a dramatic morphological change from the 
immature state. Employing atomic force microscopy (AFM), Itay Rousso’s group 
together with ours previously discovered a dramatic change in particle stiffness during 
HIV-1 maturation mediated by the cytoplasmic tail (CT) of HIV-1’s envelope protein 
(Env). A correlation between high particle stiffness and weak viral entry activity led us to 
investigate whether viral particle stiffness directly regulates viral entry activity.  
First, after observing that standard viral purification conditions perturb virion structure 
and stiffness, we determined new purification conditions that preserve both. Next, we 
showed that CT alone is sufficient to regulate viral particle stiffness. This observation 
allowed us to independently increase particle stiffness using a construct that lacks the 
Env ectodomain and thus has no entry ability itself. Using this system, we showed that 
particle stiffness directly regulates the entry activity of the Env proteins of both HIV-1 
and the unrelated Vesicular Stomatatis Virus (VSV). These results suggest a general role 
for particle stiffness in the regulation of viral entry, linking viral physical properties and 
biological functions. Mutagenesis studies reveal the important domains within CT or Gag 
  
that regulate viral entry activity. Employing an Env mutant with cleavable CT, we 
obtained preliminary data about the timing of CT’s regulation of particle stiffness. Taken 
together, these studies improve our understanding of viral structure and function during 























TABLE OF CONTENTS 
ABSTRACT                                                                                                                       iii 
LIST OF FIGURES                                                                                                           vii       
ACKNOWLEDGEMENTS                                                                                                ix     
Chapter 
1. INTRODUCTION TO HIV-1 STRUCTURE AND ENTRY                                   1 
The HIV Pandemic                                                                                                              1 
HIV-1 Virion and Lifecycle                                                                                                 2 
HIV-1 Maturation                                                                                                                3 
Gag and PR Cleavage                                                                                                          4 
MA and Membrane Targeting of Gag                                                                                 6 
CA, NC and Gag Assembly                                                                                               8 
Env Ectodomain and HIV-1 Entry                                                                                     12 
Env CT                                                                                                                               14 
Physical Properties of Viruses                                                                                           17 
Summary of The Dissertation                                                                                            19 
References                                                                                                                          27 
2. THE EFFECT OF PURIFICATION METHOD ON THE COMPLETENESS  
           OF THE IMMATURE HIV-1 GAG SHELL                                                         40 
Abstract                                                                                                                              41 
Introduction                                                                                                                        41 
Results and Discussion                                                                                                      42 




3. VIRION STIFFNESS REGULATES IMMATURE HIV-1 ENTRY                     45 
Abstract                                                                                                                              46 
Introduction                                                                                                                        46 
Methods and Materials                                                                                                      49 
Results                                                                                                                                53 
Discussion                                                                                                                          58 
Figures                                                                                                                               61 
References                                                                                                                          68 
Supplemental Figures                                                                                                        71 
4. HIV-1 PARTICLE STIFFNESS AND ITS REGULATION                                  81 
Abstract                                                                                                                              82 
Introduction                                                                                                                        82 
Methods and Materials                                                                                                      86 
Results                                                                                                                                89 
Discussion                                                                                                                          92 
Figures                                                                                                                               95 
References                                                                                                                        100 
Appendices 
A. PEPTIDE MIMIC OF THE HIV ENVELOPE GP120-GP41 INTERFACE      105 














LIST OF FIGURES 
Figures                                                                                                                            Page 
1-1.    Organization of the HIV-1 genome                                                                         26 
1-2.    Schematic representation of the HIV-1 life cycle                                                   26 
1-3.    HIV-1 Gag and viral structure change during maturation                                       27 
1-4.    The organization of gp41 and HIV-1 entry model                                                  28 
1-5.    Schematic representation of CT sub-domains                                                         29 
2-1.    Cryo-TEM images of immature HIV-1 particles                                                    42 
2-2.    The distribution of Gag shell completeness derived from Cryo-TEM images        43 
2-3.    Measuring the point stiffness of the Gag shell of immature HIV                           43 
3-1.    CT is sufficient to regulate immature HIV-1 particle stiffness                               61 
3-2.    Particle stiffness regulates immature HIV-1 entry                                                  63 
3-3.    Particle stiffness regulates immature entry mediated by VSVg                              65 
3-4.    GFP-TM1 does not interact with coexpressed viral Env                                       67 
4-1.    HIV-1 Gag and viral structure change during maturation                                       95 
4-2.    Mapping Gag domains important for regulating immature viral entry                   96 
4-3.    Mapping CT sub-domains important for regulating viral entry                              97 
4-4.    Isolation of CT region important for CT-Gag interaction                                       98 
4-5.    CT cleavage by reactivated PR                                                                                99 
A-1.   HIV entry model and schematic of gp41 and gp120 fragments                            107 
A-2.   Binding of gp41 fragments to gp120                                                                     108 
  
A-3.   Interaction between gp41 fragments and gp120 deletion mutants                        109 
A-4.   Binding of DSL20 mutants to gp120 and cell surface                                          110 
A-5.   Immunostaining of DSL49 and its DSL49ss on cellular membrane                     111 
A-6.   CD4-induced conformational changes in gp120                                                   112 
A-7.    Revised model of HIV entry                                                                                 113 
B-1.    Extracellular stability of HIV-1 strains                                                                 127 
B-2.    Important CT regions for extracellular stability                                                   128 
B-3.    Gag integrity is important for extracellular stability                                             129 
B-4.    Loss of stability is not due to disruption of virions or gp120 shedding                130 





















Many individuals have extensively helped me achieve this important goal of my life, 
and I owe them a debt of gratitude.  
First, I thank my parents for their unending support and love. They are my first and the 
greatest mentors that have shaped who I am today.  
Second, I thank all my professors and friends in Peking University. Peking University 
provided me one of the best undergraduate educations in biology and many other fields, 
and instilled in me the confidence and the courage to explore the world of the unknown. 
Many people have generously helped me along the path, and thanks to their help, I could 
come abroad to pursue a scientific career.  
Third, I thank Kay lab members. Especially, Dr. Debbie Eckert and two former Kay 
lab members, Brett Welch and Sunghwan Kim, have taught me almost all the basic 
research techniques, and extensively helped me through the beginning of graduate school.  
I also thank my friends from the biochemistry department and MB/BC program, who 
have helped me on experiments and shared happy moments with me.  
Fourth, I thank my committee members, Sherwood Casjens, Chris Hill, Vicente 
Planelles and Wes Sundquist. They have been very responsible and supportive of me with 
helpful advice on my projects, the use of their personal connections to help my projects 
and postdoc application, and good letters for my application to fellowship and postdoc 
labs.  
 
Fifth, I am very grateful to my mentor, Michael Kay. He is one of the nicest people I 
have ever known, and has always been patient, willing to help, inspiring and supportive. 
Thanks to his guidance, I can earn this Ph.D. degree from very limited experience and 
sense about biological research. I could have not received a better education in any other 
lab.  
Finally, I thank my beautiful and loving fiancée, Yan Zhou (Zoe). She is my greatest 





INTRODUCTION TO HIV-1 STRUCTURE AND ENTRY 
The HIV Pandemic 
Globally, an estimated 33 million people are currently living with Acquired 
Immunodeficiency Syndrome (AIDS), and approximately 2.6 million new infection cases 
and 2 million deaths were reported in 2009 (1). AIDS is caused by the human 
immunodeficiency virus (HIV), which spreads via blood or sexual transmission. After 
infection, HIV specifically attacks and destroys the host immune system and leaves 
patients vulnerable to various opportunistic infections.  
Over the past 20+ years, increased HIV prevention efforts, new treatments and 
improved access to treatment have lowered the number of new HIV infection cases and 
AIDS-related deaths (1). The currently recommended treatment, known as highly active 
antiretroviral therapy (HAART), uses a “cocktail” of anti-HIV drugs to target multiple 
events in the HIV lifecycle (8). However, due to HIV’s high mutation rate, strains with 
resistance to all available drugs are an emerging threat (9, 10). Meanwhile, due to the 
integration of the viral genome into host genome and viral latency, the patients whose 
disease is under control still require medication for the rest of their lives to suppress the  
 
infection (11). Therefore, additional research on HIV is still urgently needed to develop 
new strategies for more effective prevention and treatment.  
HIV-1 Virion and Lifecycle 
HIV belongs to the family Retroviridae and the genus Lentivirus. HIV can be divided 
into two major types, HIV type 1 (HIV-1) and type 2 (HIV-2). HIV-1 is the most common 
and pathogenic group (12, 13), and is the focus of this thesis. The genetic material of each 
virion includes two copies of single-stranded, positive-sense, nonsegmented RNA, which 
is ~9 kilobases (kb). HIV-1’s genome encodes nine open reading frames (Fig.1-1). The 
major structural component is the Gag polyprotein, which is proteolytically processed by 
HIV-1 protease (PR) during maturation into structural proteins MA (forms the matrix), 
CA (forms the capsid), NC (forms the nucleocapsid), and nonstructural proteins p1, p2, 
p6. Envelope (Env) polyprotein, which mediates viral entry, is initially synthesized as a 
precursor protein (gp160) and then proteolytically processed into gp120 (surface subunit) 
and gp41 (transmembrane subunit). The Pol polyprotein is another precursor protein 
which is cleaved into PR (protease), RT (reverse transcriptase) and IN (integrase). Other 
viral proteins include the regulatory proteins Tat and Rev, and the accessory proteins Nef, 
Vpr, Vif and Vpu (14).  
The lifecycle of HIV-1 can be roughly divided into early and late events (Fig.1-2) (15). 
After recognizing the host cell surface receptors, Env mediates the fusion between the 
viral and host membranes. After entry into the cell, the virion undergoes an uncoating 
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 process to release its genetic material and incorporated enzymes into the cytoplasm. The 
ssRNA genome is converted into dsDNA by RT, which then enters the nucleus and is 
integrated into the host genome by IN. Host cell machinery replicates the viral genome 
and translates viral genes. The viral RNA genome and proteins assemble at the plasma 
membrane and bud out as immature HIV-1 particles. In the extracellular environment, 
HIV-1 undergoes a maturation process to become infectious and then enters the next 
target cell.  
HIV-1 Maturation 
HIV-1, along with almost all other retroviruses (except spumaviruses), undergoes a 
maturation process after budding out of infected cells (4, 15). Maturation is characterized 
by PR cleavage of Gag into individual Gag proteins. The individual Gag proteins and 
their relative positions are shown in Fig. 1-3 A. Nascent HIV-1 particles bud out as 
immature virions (Fig. 1-3 B, left model) (15). The outer surface of the viral particle is a 
lipid bilayer membrane that is derived from the infected cell to anchor Env and Gag 
proteins. Gag polymerizes underneath the lipid membrane forming a protein shell. During 
maturation, the morphology of viral particles is changed dramatically by PR cleavage of 
Gag. After maturation, only MA still associates with the lipid membrane, and CA forms a 
conical capsid that houses NC-RNA complex (Fig. 1-3 B, right model). The detailed 
initial timing for PR cleavage of Gag is still unclear, but it is commonly accepted that the 
immature morphology remains at least until viral release (15). 
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 The most striking feature of maturation is the dramatic morphological change of viral 
structure, which can be visualized by electron microscopy (EM) (Fig. 1-3 B, bottom 
images). The Gag shell of immature virions is roughly spherical and thick (~17-19 nm), 
surrounding an electron-lucent core (Fig. 1-3 B, left bottom EM image). In mature virions, 
the protein layer associated with viral membrane is composed of only MA and is much 
thinner (~5 nm). CA condenses to form an electron-dense, conical capsid core at the 
center of the virions, which houses NC-coated viral genome (Fig. 1-3 B, right bottom EM 
image) (16). 
Maturation plays an essential role during the HIV-1 lifecycle. Defects in PR activity or 
PR cleavage sites block maturation and completely abolish HIV-1 infectivity (15). 
Several groups including ours have reported that immature viruses have much lower 
entry activity than mature ones (4, 17, 18). This feature may help prevent reentry into 
infected cells, but more detailed studies are needed to improve our understanding of the 
biological relevance of maturation in the viral lifecycle. 
Gag and PR Cleavage 
As the major structural protein, up to 5,000 Gag molecules are estimated to 
polymerize at the plasma membrane to form a single immature HIV-1 particle (19). 
Expression of Gag is sufficient to produce viral-like particles without other viral proteins 
or viral genome (20-22). MA, CA and NC are highly conserved across different strains 
(23, 24). p6 is a small Pro-rich domain located at the C-terminus of Gag and interacts 
4
 with host ESCRT (Endosomal Sorting Complex Required for Transportation) machinery 
to facilitate viral release (23, 25-28). The function of two spacer peptides, p1 and p2 (or 
sp2 and sp1, respectively), is relatively unknown, although they appear to help regulate 
the stepwise process of virion maturation and capsid assembly (29-31).  
Due to a ribosomal frameshift that occurs at a frequency of 5-10% during Gag 
translation, each immature virion is estimated to contain ~250 molecules of Gag-Pol (19). 
Gag-Pol precursors are targeted to plasma membrane and multimerize together with Gag 
molecules to drive viral budding (23, 28). The exact mechanism to activate PR activity is 
poorly defined, but may be attributed to increasing concentration of Gag-Pol at assembly 
sites or a more active switch (32). Activated PR begins to process Gag-Pol and Gag 
polyproteins by transcleavage of each cleavage site. The cleavage rate at each site is 
different, resulting in a sequential order of cleavage. Sequential cleavage was observed in 
infected cells represented by the transient appearance of processed intermediates, and was 
also shown using an in vitro Gag processing assay (29, 30, 33). The in vitro assay at pH 7 
showed the order of cleavage as p2/NC > p1/p6 ~ MA/CA > NC/p1 > CA/p2, with a 
maximal difference in cleavage rate of 400-fold (30, 31). In contrast, at pH 5 which is 
near the optimal condition for PR activity, only a ~15-fold difference in cleavage rate was 
observed. These results suggest that cleavage site sequences are optimized for the 
maximal cleavage rate difference at physiological pH. Gag mutants with one or more PR 
cleavage sites mutated have been constructed, but their effects on PR cleavage rate have 
not been investigated (18).  
5
 MA and Membrane Targeting of Gag 
Located at the N-terminus of Gag, a major function of MA is to direct Gag to the 
assembly sites at the plasma membrane (23). During Gag translation, the N-terminal 
methionine of MA is replaced by the saturated, 14-carbon fatty acid (myristic acid), 
which is required for virus assembly and Gag targeting to plasma membrane (16, 20, 34). 
Meanwhile, a cluster of conserved basic residues near the N-terminus of MA is also 
implicated in membrane binding of Gag (35, 36). Therefore, it has been proposed that the 
membrane targeting of MA is fulfilled by insertion of the N-terminal myristyl group into 
the lipid bilayer and binding of the positively charged residues to acidic phospholipids at 
the inner face of the lipid bilayer (24, 35-38). This model is supported by structural study 
of the HIV-1 MA protein (38). Studies of other retroviral MA structures also showed that 
MA exposes positively charged side chains that may function to interact with the inner 
face of lipid bilayer (39-41).  
Besides the N-terminal domain of MA, the rest of MA and other Gag proteins are also 
involved in modulation of Gag’s membrane binding. Mutations in the middle or near the 
C-terminus of MA can recover the defect of Gag membrane binding caused by mutations 
at the N-terminus of MA (42). MA itself is found to bind with membrane less efficiently 
and exclusively than intact Gag, and deletions in the C-terminus of MA enhance 
membrane binding (43, 44). The myristyl group can adopt two conformations: exposed 
and hidden (44, 45). Based on these observations, a “myristyl switch” model of 
membrane binding has been proposed in which the myristyl moiety is highly exposed in 
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 unprocessed Gag precursor and thus free to bind with the plasma membrane; after 
separation from downstream Gag proteins, the MA C-terminus sequesters its N-terminal 
myristyl group, which weakens membrane binding.  
This “myristyl switch” model is further supported by a recent NMR (Nuclear 
Magnetic Resonance) study of MA bound to a plasma membrane component, 
phosphatidylinositol (PI) 4,5-bisphosphate (PI(4,5)P2) (46). PI(4,5)P2 usually 
concentrates in the inner face of the lipid raft, which is enriched in sphingolipids and 
cholesterol (47, 48). Several observations suggest that HIV-1 mainly assembles and buds 
at lipid rafts (28, 49), and the specific targeting of Gag at assembly sites depends on 
PI(4,5)P2 (50). In an NMR study, Saad et al. show that PI(4,5)P2 directly binds with 
myristoylated MA, inducing a conformational change that triggers myristate exposure 
(46). Repositioning of several residues within the myristyl group upon PI(4,5)P2 binding 
makes additional hydrophobic and electrostatic interactions, which enhances the binding 
affinity between MA and PI(4,5)P2. This study shows the triggered exposure of MA’s 
myristyl group and the importance of myristyl exposure for membrane binding. It also 
provides a structural basis for specific targeting of Gag to the assembly sites.  
Furthermore, the myristyl group may function to stabilize MA oligomerization, which 
may be related to the membrane binding. NMR studies show that nonmyristoylated MA 
adopts a monomeric structure at up to millimolar concentration, while x-ray diffraction 
study suggests that nonmyristoylated MA crystallizes as a trimer (37, 38, 51). Wu et al. 
show that at a concentration of >100 M, nonmyristoylated MA stays as a monomer 
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 while myristoylated MA predominately exists as a trimer (52). They further show that 
myristoylation promotes thermal stability of the MA oligomer in solution (52). 
Considering that the myristyl group may become partially hidden after maturation, one 
can speculate that PR cleavage of Gag weakens the matrix layer stability, which may 
lower the energy barrier for membrane fusion. 
Another important function of MA is to interact with Env CT and facilitate Env’s 
incorporation into virions, which will be discussed in more detail below.  
CA, NC and Gag Assembly 
CA is believed to be the major driving force of Gag polymerization during viral 
assembly and forms the conical protein shell (capsid) surrounding the viral RNA genome 
and associated proteins in mature virions. CA also plays an important role in early 
postentry events, such as uncoating (23). The CA protein contains two domains: an 
N-terminal domain (NTD) that is composed of seven -helixes, two -hairpins and an 
exposed loop; and a C-terminal domain (CTD) that is also highly helical (23).  
Another Gag structural protein, NC, mainly functions in RNA binding and 
encapsidation (23). NC contains two zinc finger motifs similar to the motifs found in 
many DNA binding proteins, and these motifs are highly conserved among retroviruses 
(53). However, NC has been also implicated in other aspects of the viral lifecycle, 
including Gag-Gag interaction, RNA dimerization, and reverse transcription (23).  
Once transported to assembly sites, Gag polymerizes to form a new viral particle. The 
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 polymerization of Gag molecules is driven by lateral interactions throughout the whole 
Gag polyprotein, although some specific regions are particularly important. MA mainly 
functions to target Gag molecules to the assembly sites, which tethers Gag together and 
may provide the initial driving force for multimerization. MA may also play a role in 
Gag-Gag multimerization (54). However, Gag can assemble to form immature particles 
without MA, leading to the current idea that MA is largely dispensable for Gag-Gag 
interactions (55). MA and CANTD are connected by a flexible linker, and MA 
conformation does not change when tethered to CANTD (56). This observation supports 
the idea that MA is rather flexible and isolated from downstream Gag interactions. 
Similarly, p6 does not contribute much to Gag-Gag contacts (24). In contrast, CA, NC 
and the spacer peptide between them, p2, are believed to make critical contacts for Gag 
assembly (24). 
Mutational studies on CA have defined specific sequences important for viral 
assembly. CACTD has been suggested by mutational and structural studies to play an 
important role in Gag-Gag multimerization and viral assembly (57-60). A minimal Gag 
construct containing only CACTD and p2 can support efficient particle production (61). 
CACTD contains the only region in Gag that is highly conserved among different genera of 
retroviruses: the major homology region (MHR) (62). CA dimerizes in solution, and 
CACTD constructs have been crystallized as dimmers (57, 63). Mutations disrupting these 
intermolecular interactions reduce Gag dimerization in vitro and inhibit formation of 
immature particles (64, 65). These results support that CACTD is the driving force for CA 
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 dimerization and Gag assembly. CA is also required for incorporation of Gag-Pol 
precursor into virions (66-68). Biochemical studies also identify two regions in CANTD 
important for immature virion formation (65, 69, 70). A model has been proposed that 
CANTD provides symmetric intermolecular contacts to stabilize the Gag lattice, supported 
by structural and mutational studies (71-73).  
Studies of HIV-1 NC mutants also show the important role of this domain in viral 
assembly. The N-terminal basic residues of NC seem to be particularly important in this 
regard (74-76), and these residues promote intracellular Gag assembly in an 
RNA-dependent way (75). These results suggest that NC may promote Gag assembly via 
its interaction with RNA to tether Gag molecules together, and its basic residues may also 
provide additional Gag-Gag contacts. Replacement of NC by a protein that can form 
interprotein contacts permits efficient viral assembly even without RNA (76). NC also 
appears to play a role in the tight packing of Gag in immature virions, based on the 
observation that deletions in NC lead to the production of viral particles with lighter 
density (77). This density alteration is not attributed to the basic residues (78). 
Two recent electron cryo-microscopy (cryoEM) studies on immature HIV-1 provide 
more details on the organization of immature Gag lattice. In both studies, the Gag lattice 
is seen to be composed of close-packed, cup-shaped hexamers (71, 79). CA and p2 layers 
seem to form the walls and bottom of the cup-shaped hexamer, respectively (71). CACTD 
makes both inter- and intrahexamer interactions in the immature Gag lattice (71). This 
observation is consistent with previous reports that the region from the CA C-terminus to 
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 p2 is essential for immature particle formation (80, 81). The N-terminal MA layer lacks 
the hexagonal order, although it has been shown that MA proteins can form both trimers 
(38, 46) and hexamers (82) in vitro. On the other end, NC and viral RNA form a 
disordered layer (79). Although incompleteness of Gag lattice is seen in both studies, we 
have shown that this incompleteness is exaggerated by pelleting of viral particles through 
a sucrose cushion (83) (Chapter 2).  
Structural studies of the Gag lattice also reveal an interesting change of its packing 
pattern during maturation. CA protein can assemble in vitro into two distinct hexagonal 
arrangements: tightly and loosely packed (84). The tightly packed arrangement is similar 
to the Gag lattice in the immature virions, where the hexamer-to-hexamer spacing is in 
the range of 65-80 Å (19). On the other hand, the loosely packed arrangement 
corresponds more to the organization of the mature capsid core, where the interhexamer 
spacing is ~95-110 Å (85, 86). A more intact Gag construct, which includes MA, CA, p2 
and NC, assembles in vitro into hexamer rings with a spacing of 79.7Å (87). These results 
suggest that the presence of other Gag domains in immature virions makes CA more 
compatible with a tightly packed arrangement, and PR processing of Gag during 
maturation yields a more loosely packed capsid core. The tight-to-loose packing change 
may represent a strategy of viral structure rearrangement to lower the energy barrier for 
better entry and fusion, and may be accompanied by changes in viral physical properties.  
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 Env Ectodomain and HIV-1 Entry 
After maturation in the extracellular environment, HIV-1 virions circulate until entry 
into the next target cell. HIV-1 is commonly thought to enter target cells by membrane 
fusion at the plasma membrane, though a recent study claims endocytosis as the main 
entry route (88). The viral envelope (Env) glycoproteins, gp120 and gp41, are necessary 
and sufficient to mediate viral entry (89). gp120 and gp41 are initially synthesized as a 
precursor protein, gp160. Following cotranslational glycosylation and oligomerization, 
gp160 is cleaved in the Golgi complex by a cellular protease, Furin, after 
Arg508-Glu-Lys-Arg511 to produce gp120 and gp41 (90, 91). This processing is 
necessary to activate Env for viral entry. HIV-1 Env has been reported to be transported 
to the plasma membrane via intracellular CTLA-4-mediated secretory granules, although 
the detailed mechanism is still unclear (28). The gp120-gp41 complex forms trimeric 
spikes on the viral surface (92). gp41 contains a transmembrane (TM) domain that anchor 
Env on the viral surface, and gp120 interacts noncovalently with gp41.  
gp120 mediates target cell recognition by interacting with cellular receptor and 
coreceptors. CD4 and a seven-transmembrane, G protein-coupled chemokine receptor 
(typically CCR5 or CXCR4) on target cells, such as CD4+ T cells or macrophages, have 
been identified as the receptor and coreceptor, respectively (89). gp41 provides the 
driving force for membrane fusion via a series of conformational changes. The 
ectodomain of gp41 includes an N-terminal fusion peptide, which inserts into the host 
cell membrane during entry, and two helical heptad repeat regions termed the N- and 
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 C-peptides (Fig. 1-4 A). There is a short linker region between the N- and C-peptide 
regions containing an intramolecular disulfide bond, which we refer to as the DSL 
(disulfide loop) region. Several groups have solved the structure of the gp41 ectodomain 
in its most stable postfusion state (5, 93-95). In this structure, three N-peptides form a 
trimeric coiled coil (N-trimer) and three C-peptides bind antiparallel into the grooves of 
the N-trimer to form the postfusion structure (six-helix bundle or trimer-of-hairpins).  
The current model of HIV-1 entry is described as follows (Fig. 1-4 B). In the native 
state before entry, most of the gp41 ectodomain, including the fusion peptide, is covered 
by gp120. The first step of viral entry is the encounter of gp120 and CD4, which induces 
further conformational changes in gp120 that expose a coreceptor binding site. Moreover, 
CD4 binding also induces a conformational change in gp41 leading to the formation and 
partial exposure of the N-trimer region (prehairpin intermediate state). This model is 
supported by the fact that exogenous C-peptide can transiently access and bind to the 
gp41 N-trimer region after CD4 binding (96, 97). Subsequent coreceptor binding with 
gp120 may induce further exposure of the N-trimer region. Eventually, C-peptides bend 
over and bind with the N-trimer to form a six-helix bundle, which drives host cell and 
viral membranes together to achieve fusion.  
The gp41 postfusion structure is its most stable state. The existence of the prehairpin 
intermediate state suggests that gp41 must have a metastable prefusogenic state in which 
N- and C-peptide are separated. This metastable structure is very likely to be stabilized by 
the gp41-gp120 interaction, which is eventually disrupted by CD4 and coreceptor binding, 
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 leading to formation of the six-helix bundle structure. The prefusogenic intermediate state 
of gp41 has been an attractive target for HIV-1 entry inhibitor and neutralizing antibody 
development. A peptide derived from the C-peptide sequence has been approved for 
AIDS treatment (Fuzeon). Several D-peptide inhibitors specifically targeting a conserved 
hydrophobic pocket region on the N-trimer have been developed by the Kay lab (7, 98). 
Vaccine development targeting the N-trimer, on the other hand, has been challenging 
partly due to a steric restraint caused by associated gp120. Detailed structural information 
about the gp41-gp120 complex and the prefusogenic state is urgently needed. In the 
intermediate state, the N- and C-peptides must be separated from each other to prevent 
formation of a six-helix bundle, and separation is most likely attributed to gp120. We 
have identified the gp41 DSL plus the N-terminal C-peptide region (DSL49) as being the 
most critical for interaction with gp120, while the N-peptide region is dispensable (99) 
(Appendix A). DSL49, which cannot form a six-helix bundle, may provide an important 
tool for obtaining the gp41 prefusogenic structure (in complex with gp120). 
Env CT 
HIV-1 together with other lentiviruses has a relatively long CT including ~150 amino 
acids (aa), which extends into the interior of the virion and makes contacts with MA (4, 
100, 101). In contrast, other retroviruses have a much shorter CT with ~20-30 aa (100, 
101). CT has been shown to be critical for Env incorporation in primary cell types that 
serve as natural targets of HIV-1 (100). However, little is known about the detailed role of 
14
 CT in the viral lifecycle.  
Currently, there is no high-resolution structural data available for the Env CT domain, 
but several structural features have been predicted and their functions implicated by 
mutagenesis studies (Fig. 1-5). Although CT has no typical membrane binding sequences, 
three highly conserved amphipathic -helical secondary structures have been proposed to 
bind with the membrane (102). Peptides with these segment sequences have also been 
shown to decrease bilayer stability, alter membrane permeability, and cause cytolytic 
effects, leading to the naming of these segments as “lentivirus lytic peptides” (LLP-1, 
LLP-2 and LLP-3) (103-105). Among these, LLP-1 has been further shown to be 
important for lipid raft association of Env (102).  
CT is responsible for rapid internalization of HIV-1 Env, which reduces the 
susceptibility of infected cells to the host immune system. A tyrosine-based YxxL 
endocytic motif at the N-terminus of CT interacts with the 2 chain of the AP-2 clathrin 
complexes to induce Env internalization (106-109). A dileucine motif at the C-terminus 
of CT is also responsible for Env internalization through interacting with clathrin and 
AP-2 (110). This dileucine motif also interacts with AP-1 to affect Env expression level 
on the cell surface and subcellular localization (111). Two inhibitory sequences around 
one of CT’s palmitylated Cys (C762, HXB2 numbering) are also reported to lower the 
surface Env level (112). A diaromatic motif (YW801) is involved in interactions with 
cellular protein TIP47, which may function to target Env to the Golgi network (113). 
HIV-1 Env is concentrated in lipid rafts on infected cell membranes. Two palmitylated 
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 Cys residues have been shown to be important for Env localization to lipid raft regions 
and viral infectivity (114-116).  
Env can interact with Gag intracellularly, but can only be assembled onto viral 
particles on the plasma membrane (28). Several lines of genetic and biochemical 
evidence have established that Env CT interacts with MA, and this interaction is 
important for Env incorporation. First, mutations in MA inhibit WT Env incorportion into 
virions, which can be restored by truncation of CT (117-120). Similarly, a single amino 
acid change in MA can reverse the incorporation defect caused by a small deletion in CT 
domain (121). Second, Env expression is essential to direct Gag assembly at the 
basolateral surface of polarized epithelial cells, and mutations in MA or truncation in CT 
eliminate this polarized budding (107, 122, 123). Third, coexpression with Gag inhibits 
the rapid internalization of Env mediated by endocytotic motif located within CT (124). 
Fourth, a detergent-resistant interaction was reported between Env and Gag, which is 
dependent on CT and MA (125, 126). Finally, a direct interaction between CT and MA 
was reported in vitro using recombinant CT and MA proteins (127). 
Besides interacting with other viral components and host proteins, CT can also affect 
the Env ectodomain conformation (“inside-out” signaling). Identified from screening 
CD4-independent variants, an Env mutant bearing a 27 aa C-terminal CT truncation was 
shown to expose highly conserved gp120 domains involved in both CD4 and coreceptor 
binding, induce antigenic changes in the gp41 ectodomain and increase sensitivity to 
neutralizing antibodies (128). CT truncations proximal to LLP2, which is located near the 
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 middle of CT, show a similar effect increasing fusion efficiency and exposing 
CD4-induced epitopes (129). In contrast, a point mutation in LLP2 can render viruses 
resistant to broadly neutralizing antibodies, while the receptor binding and viral 
infectivity remain unchanged (130). These results suggest that CT alteration can induce 
conformational changes in the gp41 ectodomain and gp120 that affect viral fusion and 
sensitivity to the host immune response, though the mechanism remains unclear.  
Physical Properties of Viruses 
During the viral lifecycle, several potentially conflicting demands must be met, such 
as spontaneous assembly during budding, durability in the extracellular environment, 
efficient membrane fusion and disassembly after entry into a target cell. Therefore, we 
speculate that the virus may have different physical properties at distinct phases of its 
lifecycle. During maturation of retroviruses, the internal structural organization changes 
dramatically while the overall size of viral particles does not. The molecular and 
morphological change during maturation has been well characterized by biochemical and 
various EM imaging techniques (15). However, little is known about the impact of 
maturation on viral physical properties.  
AFM has been most commonly used in biology as a tool to obtain high-resolution 
topographical images in various samples including HIV-1. Recently, the Rousso group 
has measured the spring constants for two retroviruses, Murine Moloney Leukemia Virus 
(MLV) and HIV-1, to determine viral particle stiffness (4, 131). The uniqueness of these 
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 studies is that compared to EM, which requires sample fixation, AFM can measure 
unfixed viral particles. Using AFM, several groups also reported mechanical property 
measurements on capsids of several other viruses, e.g. bacteriophage (132), cowpea 
chlorotic mottle virus (133) and minute virus (134). In MLV, AFM reveals a clear 
difference between mature and immature MLV particles, in which immature particles are 
two-fold stiffer than mature ones (131). 
In contrast, for HIV-1, immature virions are ~14-fold stiffer than mature ones, a much 
more dramatic change than observed with MLV that we dubbed the “stiffness switch” (4). 
Further investigation of Env’s role in this stiffness change reveals that deletion of Env, or 
only CT, dramatically softens immature particles to near the mature level, showing that 
Env CT is required for the stiffness switch. Since viral entry is the next step after 
maturation, we speculate that the stiffness switch may have a role in regulating viral 
entry activity. In agreement with previous reports, we observed that immature HIV-1 
enters target cells ~10-fold less efficiently than mature HIV-1, and deletion of CT in 
immature virions largely restores their entry activity to the mature level. These results 
suggest an inverse correlation between particle stiffness and viral entry activity. However, 
truncation of CT can also induce conformational changes on the Env ectodomain, which 
could alter viral entry activity. Therefore, a cause and effect relationship between particle 
stiffness and viral entry cannot be proven by the above observation. Further studies are 
needed to elucidate the nature of viral particle stiffness, and its biological relevance 
during the HIV-1 lifecycle.  
18
 Summary of The Dissertation 
Chapter 2 
Recent cyroEM studies of the immature Gag lattice show incorporation defects in the 
forms of gaps of various sizes (~40%-70% of Gag lattice completeness) (71, 79). All 
these immature virions were purified by pelleting through a sucrose cushion, which has 
been a standard method in HIV-1 studies. We asked whether sucrose purification is 
damaging the immature Gag shell by osmotic shock or the mechanical force during 
centrifugation, leading to large observed gaps. We previously reported that immature 
HIV-1 has much higher particle stiffness than mature ones, which argues against the idea 
that the immature Gag lattice has large gaps (4). Therefore, we wonder whether a gentler 
method of purification method would preserve the stiffness of immature HIV-1 to a 
higher degree. A comparison of morphology and stiffness was conducted between viruses 
purified by sucrose or Iodixanol, a nonionic density gradient media also known as 
OptiPrep. Viruses purified by OptiPrep were found to have a much higher degree of 
completeness in Gag lattice and particle stiffness, suggesting that purification method 
does affect the integrity of the immature Gag shell. I played a supporting role in this study, 
which was published in the Journal of Virological Methods in 2010.  
Chapter 3 
In this chapter, we aimed to prove the cause-effect relationship between particle 
stiffness and viral entry. To achieve this goal, it was necessary to separate the entry and 
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 stiffness properties of HIV-1 Env. First, we showed that CT alone is sufficient to regulate 
the particle stiffness of immature HIV-1. Using a CT-containing construct that has no 
viral entry activity due to lack of the Env ectodomain, we were able to independently 
stiffen the immature particles. Increasing particle stiffness was shown to reduce viral 
entry mediated by the Env proteins of different HIV-1 strains and VSV (Vesicular 
Stomatitis Virus), which is unrelated to HIV-1 and enters the target cells via endocytosis. 
These results support the hypothesis that particle stiffness directly regulates viral entry, 
regardless of viral type or entry route. In this work, I did everything except for the AFM 
measurement, and it is nearly ready to be submitted pending AFM control measurements.   
Chapter 4 
In this chapter, we aimed to identify the critical factors that regulate viral particle 
stiffness and clarify how particle stiffness is regulated. Both CT and Gag processing have 
been suggested to affect the particle stiffness change during HIV-1 maturation (4). A 
series of CT truncation mutants and partially maturated Gag mutants were employed to 
identify the critical subdomains important for particle stiffness. So far, a region near the 
N-terminus of CT was shown to be important for suppression of immature viral entry. In 
agreement with a previous report, we also found that this region is critical for Env-Gag 
interaction (6). Studies with Gag mutants also showed that the integrity of Gag structural 
domains is essential to suppress viral entry.  
We propose two models for how CT might regulate particle stiffness: first, CT 
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 functions during viral assembly to seed the initial formation of the Gag shell; second, CT 
functions to stabilize the Gag shell by its interaction with Gag. To distinguish these two 
models, the timing of CT’s effect on stiffening immature particles needed to be defined. 
Using an Env mutant with a CT that could be cleaved by HIV-1 PR, we were able to 
control the CT cleavage time so that it followed viral budding. Initial viral entry 
measurement showed that immature particles in which CT was cleaved after budding had 
similar entry activities that were similar to immature WT, suggesting that CT is only 
important for enhancing particle stiffness during assembly. I have finished the majority of 
work that I am responsible for, and AFM measurement of all these viruses is pending.  
Appendix A 
During HIV-1 entry, CD4 and coreceptor binding induce a series of conformational 
changes to gp120. gp120 then transmits these entry signals to gp41 via their interaction, 
leading to exposure of gp41 and eventually formation of the six-helix bundle structure 
that drives membrane fusion. However, the interface of the gp120-gp41 complex is 
poorly understood, slowing our understanding of the HIV-1 entry process and 
development of novel entry inhibitors. Here, we identified a critical interface of the 
gp120-gp41 complex that is required for stabilizing the prehairpin intermediate gp41 
conformation. This interaction needs to be disrupted in order to form the six-helix bundle. 
This study identifies the critical regions in gp120 and gp41 that mediate activation of 
gp41 during entry. I played a supporting role in isolation of the minimal DSL region for 
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 gp120 binding, which was published in the Journal of Molecular Biology in 2008.  
Appendix B 
After maturation, HIV-1 virions stay in the extracellular environment until entry into 
the next target cell. The durability of virions is little studied except for the fact that 
mature HIV-1 infectivity decays rapidly. In this study, we discovered that immature 
HIV-1 can preserve its entry activity much better than mature virions. Deletion of CT or 
PR cleavage of Gag disrupts this stability of immature viral entry activity. Stiffening of 
immature ∆CT virions does not restore extracellular stability. Preliminary studies reveal 
that neither gp120 incorporation level nor CD4 binding ability changes with deletion of 
CT in the immature state. The underlying mechanism for extracellular stability change of 















Fig 1-1. Organization of the HIV-1 genome.  
Details are provided in the text. On the 5’ and 3’ ends of genome are two long 
terminal repeats (LTRs). Figure is adapted from (2). 
Fig 1-2. Schematic representation of the HIV-1 life cycle.  








Fig 1-3. HIV-1 Gag and viral structure change during maturation 
(A). Schematic representation of HIV-1 Gag domains.  
(B). Schematic models (top) and EM images (bottom) of HIV-1 immature and 
mature virions. Viral lipid membrane is labeled in purple and HIV-1 Env trimer 
spikes are in brown. HIV-1 Env does not undergo proteolytic processing during 
maturation. For simplicity, the nonstructrual Gag proteins (p1, p2 and p6) are not 
included in the virion model. The models are adapted from (4) and the EM images 













Fig 1-4. The organization of gp41 and HIV-1 entry model.  
(A). Schematic representation of gp41 domains. On the N-terminus of gp41 is 
the fusion peptide (fp). The transmembrane (TM) and cytoplasmic tail (CT) 
domains are at the C-terminus. (B). Model of HIV-1 entry. The gp41 scheme is 















Fig 1-5. Schematic representation of CT sub-domains.  





, and two inhibitory sequences (is1 and is2) are in the text. The 
figure is adapted from (6). 
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a b s t r a c t
Elucidating the structure of the immature HIV-1 Gag core is an important aspect of understanding the
biology of this virus. In doing so, preservation of the fragile Gag lattice is essential. In this study, the effects
of purificationmethods on the structural andmechanical integrity of immature HIV-1 are examined. The
results show that the morphological and mechanical properties of the virion are preserved to a signifi-
cantly higher degree by Iodixanol (OptiPrep) purification compared to the standard sucrose method. In
conclusion, these results indicate that OptiPrep instead of sucrose purification should be employedwhen
conducting structural studies on the HIV-1 virion.
© 2010 Elsevier B.V. All rights reserved.
Gag is the structural protein of HIV-1, which comprises the
core of the virion and drives its assembly and budding at the
plasma membrane. HIV-1 buds as a non-infectious immature par-
ticle, composed of a dense doughnut-like shell consisting of Gag,
located directly underneath the viral membrane. The Gag polypro-
tein includes three main structural domains – MA, CA, and NC,
which are cleaved after budding by the viral protease to form the
mature infectious virion. The mature virus particle has a distinctly
different morphology and contains a conical capsid.
Elucidating the structure of the immature virion’s Gag shell
has been the focus of several studies, as it may resolve important
questions associated with the assembly, budding, and maturation
processes of HIV-1. Initially Gag was assumed to generally form a
complete lattice beneath the viral lipid bilayer membrane. Later it
was shown that the lattice is hexagonal (Briggs et al., 2006, 2004;
Mayoet al., 2003;Nermutet al., 1998), the closureofwhich requires
the presence of defects. Defects can either be in form of pentamers
at each of the 12 vertices yielding an icosohedral virion, like in the
case of many viruses such as HSV, adenovirus, and bacteriophage,
or gaps in the hexagonal lattice. In the last decade, several stud-
∗ Corresponding author. Tel.: +972 8 9343479; fax: +972 8 9344136.
E-mail address: itay.rousso@weizmann.ac.il (I. Rousso).
ies suggested that closure of the HIV shell is accomplished by the
incorporation of defects in the form of gaps of various sizes (Briggs
et al., 2009; Carlson et al., 2008; Fuller et al., 1997;Wilk et al., 2001;
Wright et al., 2007). The most recent studies used electron cryoto-
mography to estimate the size and nature of these gaps (Briggs et
al., 2009; Carlson et al., 2008; Wright et al., 2007). The first study
found the Gag shell to be∼40% complete on average and to consist
of several patches of Gag lattice (Wright et al., 2007). Two recent
studies from the Krausslich group showed that the Gag shell has an
average completeness of ∼70% and consists of one continuous lat-
tice that contains small gaps throughout (Briggs et al., 2009;Carlson
et al., 2008). All of these studies were carried out on viruses that
were purified by pelleting through a sucrose cushion, a method
that is used commonly in the HIV field. In the past, concerns were
raised about the use of sucrose solutions to purify retroviruses due
to possible damage by osmotic shock and the need for pelleting
by ultracentrifugation. In fact, extensive damage to virus glycopro-
teins was indeed demonstrated using this method (McGrath et al.,
1978;Moennig et al., 1974). Therefore the structure of theGag shell
of the immature HIV-1 virion in its native state remains unknown.
It has previously been reported that the Gag shell of the imma-
ture HIV-1 particle is mechanically rigid (Kol et al., 2007). This
finding is difficult to reconcile with the idea that the Gag shell is
discontinuous and has large gaps. In this study, the impact on virus
0166-0934/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.jviromet.2010.07.035
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structure by the virus purification method is investigated. More
specifically, it was asked if a gentler method of purification would
preserve the completeness of the immature HIV-1 shell to a higher
degree.
A comparison of the morphology and stiffness of virus particles
purified using sucrose or Iodixanol, a non-ionic density gradient
media also known as OptiPrep was conducted. 293T cells were
transfectedwith the pNL-MA/p6 vector, which produces immature
HIV-1 particles (Wyma et al., 2004), using the PEI protocol (Boussif
et al., 1995). 18–20h post-transfection, media was exchanged, and
60mlof viral supernatantwas collectedafter6h. Thefiltered super-
natant was split into two parts. One half was pelleted through a
5-ml cushionof20%sucrose inTNEbuffer (0.15MNaCl, 1mMEDTA,
10mM Tris, pH 7.6) in a SW-28 rotor (25,000 rpm, 1h). The virus
pellet was resuspended in TNE by gentle pipetting and stored at
4 ◦C. The other half of the filtered supernatant was pelleted onto
a 5-ml cushion of OptiPrep in a SW-28 rotor (21,000 rpm, 1.5h).
The supernatantwas then aspirated, leaving 2–3ml ofmedia above
the cushion, containing the concentrated virus, and the cushion
was then removed with a syringe. The remaining supernatant was
combined with TNE and concentrated by centrifugal ultrafiltration
with a MWCO of 100,000 (Vivaspin 20, Sartorius, Goettingen, Ger-
many). Viruswas concentrated from20 to 1ml at 3000× g and then
washedwith TNE by repeating this procedure three times. The final
volumeof approximately 500!l was removed and stored at 4 ◦C for
up to 3weeks, duringwhich time no changes in virus structure and
mechanical properties were observed.
1. Effects on virus morphology
The morphology of the purified virions was studied by exam-
ining the projections of virions using Cryo-TEM. 4!l of virus was
deposited on amicroscope grid, either Quantifoil or lacey (Electron
Microscopy Sciences, Hatfield, PA), which was soaked previously
in chloroform, and rendered hydrophilic using glow discharge. The
grids were immediately inserted into liquid ethane. Images were
acquired on a Tecnai T12 electron microscope (FEI, Hillsboro, OR)
under low dose regime. Fig. 1A and B show representative images
from the sucrose and OptiPrep-purified samples, respectively. At
a qualitative level, it is clear that while the viruses purified using
the sucrosemethod typically display only a partial Gag layer, those
purified using the OptiPrep method show a much more complete
layer, which usually runs along most, if not all of the interior of the
viral membrane.
In order to quantify the extent of this difference, the portion of
the virus circumference that had a Gag layer underneath was ana-
lyzed by identifying the boundaries of the shell manually (Fig. 1
arrowheads) and calculating the percentage of completeness by
dividing this length by the overall virus circumference. The results
show that the Gag shell of viruses purifiedwith the sucrosemethod
(Fig. 2A) is significantly more incomplete than that of the viruses
purified using OptiPrep (Fig. 2B). While the mean coverage of the
sucrose-purified viruseswas only 60±18%, that of the viruses puri-
fied using the OptiPrep method was 82±16% (64 particles were
analyzed in each group with the standard deviation indicated).
Moreover, there were three times as many viruses that displayed
a complete shell using the OptiPrep vs. the sucrose method (33%
vs. 9%). Student’s t-test showed the difference between the two
populations to be highly significant (P<0.0001).
2. Effects on virus stiffness
Tocomplement the structural analysis, the stiffnessof immature
virus particles purified with the sucrose or the OptiPrep methods
was measured. Virus particles were attached to glass slides that
Fig. 1. Cryo-TEM images of immature HIV-1 particles. The Gag shell in the projec-
tions of viruses purified with the sucrose method (A) is less complete than that of
viruses purified using OptiPrep (B). The black arrowheads mark the beginning and
endof the continuous shell.White arrowheadsmark a secondGag segment. Absence
of arrowheads indicates a virion with a complete shell.
were renderedhydrophobicwithHMDS, and the surfaceof the slide
was scanned with a Bioscope AFM (Veeco, Santa-Barbara, CA) until
particleswere located. The tipof theAFMwas thenpositioned in the
center of the virion and used to compress the particle. The response
of the particle to the applied force of the AFM tip is recorded in the
form of a force–distance curve, fromwhich the stiffness of the par-
ticle is derived according to a previously described method (Kol
et al., 2006, 2007). Pyramidal silicon nitride probes, either DNP
(K=0.1N/m, Veeco, Santa-Barbara) or NSC35 (K=3–7N/m, Micro-
masch, Tallinn, Estonia) were used. The spring constants of the
DNP probes were determined by measuring the thermal fluctua-
tions (Hutter and Bechhoefer, 1993) and of the NSC35 probes by
the method developed by Sader et al. (1999). The use of different
methods was necessary due to the low amplitude of the thermal
fluctuations of the NSC35 probes. While viruses purified using the
two methods appeared identical when imaged by the AFM, their
response to the applied force varied greatly. Virions purified using
the sucrosemethodwere significantly softer than particles purified
using OptiPrep (0.3±0.01N/m (n=23) and 15±0.7N/m (n=19),
respectively). In a previous study, the stiffness of immature virus
particleswas significantly reduced by removal of the viral envelope
protein (gp160). It is therefore possible that lower gp160 levels in
sucrose-purified virus particles contribute to their reduced stiff-
ness. However, Western-blot analysis of virus particles purified
42
246 N. Kol et al. / Journal of Virological Methods 169 (2010) 244–247
Fig. 2. The distribution of Gag shell completeness derived from Cryo-TEM images.
Virus particles purifiedwith (A) the sucrosemethod had an average completeness of
60% and those purified with (B) the OptiPrep method had an average completeness
of 82% (64 images of virions prepared by each method were analyzed).
using the two methods revealed similar levels of gp160 incorpo-
ration (Fig. 3C).
Further insights into the structure of the Gag shell can be
obtained fromtheshapeof the force–distancecurves.Whenastruc-
tured protein layer exists beneath the membrane, the resistance
of the particle to the force is approximately linear. In contrast, in
the absence of a structured layer, the particle behaves much like a
vesicle, the stiffness of which increases monotonically as it is com-
pressed. In this manner, the AFM can be used as a complementary
method to the cryo-EM analysis to probe the completeness of the
Gag shell. All the force–distance curves obtained from virus parti-
cles purified by the OptiPrep method were nearly linear (Fig. 3A),
indicating the presence of a structured Gag layer beneath the viral
envelope.However, nearly 30%of the virus particles thatwerepuri-
fied with the sucrose method lacked an ordered layer, as evident
by the non-linearity of their force–distance curves (Fig. 3B). Thus,
the mechanical results correlate with the cryo-EM analysis.
It should be emphasized that the variability in the amount of
damage done to the virus particles using the sucrose purification
methods is significantly larger than that of the OptiPrepmethod. In
aprevious study (Kol et al., 2007), sucrosewasused topurify viruses
and the average stiffness of the immature virion was found to be
3.15N/m.Thosevirusespresumablyhadamorecomplete shell than
the sucrose-purified viruses in the current study (0.3N/m). Never-
theless, the damage to the Gag shell in all sucrose-purified virus
particles is significantly higher than that of the OptiPrep-purified
viruses, the stiffness of which is on the average 15N/m.
Fig. 3. Measuring the point stiffness of the Gag shell of immature HIV. A typical
force–distance curve of an immature virus purified using the OptiPrep method (A)
compared to that of a virus purified using sucrose (B). For reference, the cantilever
deflection is plotted (dashed black line). The response of the virus Gag shell in A is
linear whereas the stiffness of the shell in B gradually increases. (C) Western-blot
analysis of gp160 levels (green, Chessie-8 Ab) and capsid levels (red, anti-p24 Ab).
Unpurified virus particles are shown in lane 1 while sucrose- and OptiPrep-purified
virus particles are shown in lanes 2 and 3, respectively. Unpurified and OptiPrep-
purified virus particles were concentrated via centrifugation. (For interpretation of
the references to color in the figure caption, the reader is referred to theweb version
of the article.)
These results demonstrate that the purification method has a
great impact on the mechanical stiffness and the completeness of
the immature HIV-1 Gag shell. Currently it is not known which
aspect of the sucrose purificationmethod is damaging to the virus –
osmotic pressure caused by sucrose or mechanical stress imposed
on them by pelleting onto a hard surface under high centrifugal
forces. However it is clear that the OptiPrep purification method
presented in this report preserves the integrity of the immature
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HIV-1 virion to amuchhigher degree than the conventional sucrose
purification method, and should be the method of choice for the
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Human immunodeficiency virus type 1 (HIV-1) undergoes a protease-mediated 
maturation process that is required for its infectivity. Little is known about how the 
physical properties of viral particles change during this process. Using Atomic Force 
Microscopy (AFM), we previously reported a dramatic reduction in HIV-1 particle 
stiffness during maturation. In this study, we show that transmembrane anchored 
Envelope (Env) cytoplasmic tail (CT) domain is sufficient to produce stiff immature 
particles. Using this construct coexpressed with viral Env lacking the CT domain (∆CT), 
we show that particle stiffness is inversely related to viral entry activity. A similar effect 
was also observed for vesicular stomatitis virus Env (VSVg) pseudovirions. This linkage 
between particle stiffness and viral entry activity illustrates a new level of regulation for 
viral replication and defines a new inhibitory target. 
Introduction 
The main structural components of an HIV-1 particle are its protein shell, composed of 
the viral Gag polyprotein and a surrounding lipid membrane. Expression of Gag alone is 
necessary and sufficient for viral particle assembly and budding (1). The viral surface 
contains the envelope protein (Env), which is synthesized as a precursor (gp160) that is 
cleaved by a cellular protease into two subunits: a receptor-binding subunit (gp120) and a 
transmembrane subunit (gp41). gp120 and gp41 form a noncovalent complex that 
mediates viral entry (2, 3). The Env transmembrane subunit of HIV-1 (and other 
lentiviruses) has an unusually long (~150 amino acids) cytoplasmic tail (CT) domain 
compared to other retroviruses. Gag interacts with Env via CT, which is essential for Env 
localization to its budding sites and efficient incorporation into virions (4-6).  
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   New virions initially emerge from infected cells as immature particles. These 
particles undergo a maturation process in the extracellular environment induced by HIV 
protease cleavage of Gag into several products including three structural proteins: MA, 
CA and NC (7). Electron Microscopy (EM) shows that HIV particles undergo a dramatic 
morphological change from a roughly spherically symmetric immature particle with a 
thick protein shell to a mature particle with a prominent conical core (capsid) formed by 
CA (8). In mature virions, only MA remains associated with the viral membrane, creating 
a thin protein shell underlying the membrane. With such a striking morphological change, 
we hypothesized that the physical properties of viral particles would also change during 
maturation.  
During the viral lifecycle, a virion needs to meet several distinct demands—efficient 
membrane fusion during entry, particle disassembly to release genetic material, assembly 
during budding and stability in the extracellular environment before the next entry. We 
speculate that the virion may adopt different physical properties at different stages of its 
lifecycle, but the link between physical properties and viral biological activity remain 
poorly understood. To study the physical properties of viral particles, atomic force 
microscopy (AFM) has proven to be uniquely informative. In contrast to EM, AFM can 
be performed on unfixed viruses under native conditions and does not require freezing or 
fixation, which can irreversibly damage viral particles. AFM has been successfully 
applied for measuring the physical properties of several viruses (9-12). 
We previously reported that immature particles are ~14-fold stiffer than mature ones, a 
dramatic change in physical properties that we call the “stiffness switch” (13). Further 
studies determined that Env CT is required for the stiffness switch, as deletion of CT 
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softens immature HIV-1 particles almost to the mature level (13). Viral entry is the next 
event after maturation, and maturation is required for HIV infectivity. Immature HIV-1 
virions are noninfectious due to postentry deficiencies (e.g. integration) and also fuse 
with target cells with ~10-fold lower efficiency than mature virions (14, 15). We also 
verified that deletion of CT restores the entry activity of immature HIV-1 to the mature 
level, in agreement with previous studies (14, 15). Although these results suggest a strong 
inverse correlation between viral particle stiffness and entry activity, a cause and effect 
relationship has not yet been demonstrated.  
In this study, we ask whether particle stiffness of a virion directly regulates its entry 
activity. To rule out other possibilities and solely investigate the effect of particle stiffness 
on viral entry, we designed constructs that separate Env’s fusion and stiffness-mediating 
activities. Using these constructs, we show that membrane-anchored CT alone can 
mediate particle stiffness and that stiffness directly regulates viral entry. We also show 
that stiffness can regulate entry activity mediated by an unrelated viral envelope protein 
(VSVg, Env of Vesicular Stomatitis Virus). This study, to the best of our knowledge, 
provides the first direct evidence to prove that particle stiffness regulates viral entry 
activity, linking a virion’s physical and biological properties. Furthermore, our results 
suggest that particle stiffness has a fundamental effect on viral fusion independent of viral 
type or entry route. Our studies define a new regulatory level for viral replication and 




Materials and Methods 
Plasmids 
Plasmids were obtained or constructed as follows: ∆Env HIV-1 genome containing an 
inactivating integrase mutant (DHIV3-GFP-D116G (16), provided by V. Planelles), 
HIV-1 Env expression vector (pEBB-HXB2 (17), provided by B. Chen), VSVg 
expression vector (phCMV-VSV-G (18, 19), provided by W. Sundquist), Env expression 
plasmid for JRFL strain (pCAGGS-JRFL-Env WT and ∆CT, provided by Dr. James 
Binley) and vector expressing Vpr--lactamase (BlaM-Vpr) fusion protein, pMM310 
(14). Human placental alkaline phosphatase (PLAP) expressing vector (pCMV-SPORT6) 
was from ATCC. Immature particles were generated by cloning Gag with all PR cleavage 
sites mutated (pNL-MA/p6 (14), provided by C. Aiken) into the ∆Env Int− HIV-1 
genome, while mature particles were produced using an HIV-1 genome vector with 
wild-type (WT) cleavage sites. ∆CT HXB2 Env (∆147 (20)) was provided by E. Hunter 
and cloned into pEBB-HXB2.  
To construct GFP-TM1, the open reading frame (ORF) encoding GFP (green 
fluorescent protein) was obtained from pET9a-GFP-C37 (21) by PCR using 5’ 
KpnI-containing primer (5’-tctgggtacctagctctggcatggtgagcaagggcgagg) and 3’ 
SacI-containing primer (5’-ctcgaggagctcttgtacag). The ORF for TM and CT fragments 
was obtained from pEBB-HXB2 by PCR using 5’ SacI-containing primer 
(5’-caatgagctctggcggttggaattggtttaacataacaaattgg) and 3’ BamHI-containing primer 
(5’-gtcccagataagtgctaaggatc). These two PCR products are annealed at the SacI digestion 
site. The generated GFP-TM1 fusion fragment was inserted into pEBB-HXB2 to replace 
the corresponding KpnI-BamHI fragment, which includes the residues from V44 to L681 
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of Env ectodomain (HXB2 numbering).  
Viral preparation and analysis 
Pseudovirion particles were produced by cotransfection of 293T cells with ∆Env int- 
HIV-1 genome vector, an Env-expressing vector, varying amounts of pEBB-GFP-TM1 
and pMM310. For example, to generate immature or mature WT virus, 2.5 g of total 
DNA (1.23 g genome vector, 0.819 g Env expressing vector, and 0.45 g pMM310) 
was transfected into ~10
6
 cells using 10 g polyethylenimine (PEI, Sigma). The amount 
of Env expressing plasmid input for immature WT has been defined as 100% for plasmid 
input. Media was changed at 6 h after transfection to avoid PEI’s toxicity. Supernatants 
containing secreted viral particles were collected 30 h posttransfection and filtered 
through 0.2 m Acrodisc syringe filters (Pall). Each series of viruses prepared on the 
same day is defined as one “batch”. 
For western blot (WB) analysis of viral concentration and Env incorporation level, 
virus supernatants were purified by centrifugation through a sucrose cushion (20% 
sucrose in 1 X TNE buffer: 0.1 M NaCl, 1 mM EDTA, 10 mM Tris, pH 7.6) at 20,000 X 
g for 90 min at 4°C. The pellet was resuspended in SDS-PAGE reducing sample buffer 
and resolved by SDS-PAGE. WB was developed using rabbit polyclonal anti-CA and 
anti-VSVg (provided by W. Sundquist), mouse monoclonal anti-gp41 Chessie 8 antibody 
(obtained from Chessie 8 hybridoma provided by NIH AIDS Research and References 
Reagent Program (ARRRP)), sheep polyclonal anti-gp120 (contributed by M. Phelan, 
ARRRP) and rabbit polyclonal anti-BlaM (Chemicon/Millpore). Blots were quantiﬁed 
using Li-Cor’s Odyssey instrument. 
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AFM measurement and analysis 
For AFM measurement, virus-containing supernatant was first concentrated as 
previously described (22). Briefly, the filtered viral supernatnant was pelleted onto a 1-ml 
cushion of OPTI-PREP (Iodixanol, Sigma) in a SW-41 rotor (21,000 rpm, 90 min, 4°C). 
~90% of upper layer supernatant was then aspirated, and the cushion was removed with a 
syringe. The remaining supernatant was combined with 1 X TNE buffer and concentrated 
by centrifugal ultrafiltration with a MWCO of 100,000 (Vivaspin 20, Sartorius, Germany) 
for three times at 3,000 X g.   
For AFM imaging and force measurements, virus particles were attached to 
HMDS-coated microscope glass slides using a previously described method (13, 22). All 
AFM experiments were carried out using a Bioscope with a Nanoscope IV controller 
(Veeco) equipped with a dimension XY closed loop scanner mounted on an inverted 
optical microscope (Axiovert 200M, Carl Zeiss AG). Images of virus particles were 
acquired in AFM tapping mode in a fluid environment. Pyramidal silicone nitride probes 
either XXX (K=1 N/m, Veeco) or NSC35 (K=3-7 N/m, Micromasch, Tallin, Estonia) 
were used. The spring constants of the DNP probes were determined experimentally by 
measuring thermal fluctuations (23). Since the amplitude of the NSC35 thermal 
fluctuations was too low, we used the method of Sadata et al. to determine their spring 
constant. 
Virus stiffness was determined based on indentation type experiments, as previously 
described (13). Briefly, for each indentation measurement, ~100 force-distance curves 
were performed at a scan rate of 0.5 Hz. Viral stiffness was derived mathematically from 
the slope of the FD curve. The stiffness of the virus was computed according to Hooke’s 
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law on the assumption that our experimental system can be modeled as two springs (the 
virus and the cantilever) arranged in series. 
-lactamase (BlaM) assay for viral entry measurement 
The viral entry assay was performed as described (13). Briefly, HIV-1 particles mixed 
with DEAE-Dextran (4 g/ml) were added onto HOS-CD4-CXCR4 cells (provided by 
B.Chen), followed by centrifugation at 1,800 X g for 30 min at 4°C and then incubation 
at 37°C for 2 h. After removal of unbound viruses, 1 M -lactamase substrate solution 
(CCF2-AM, Invitrogen) was incubated with cells at 13°C for 17 h. Uncleaved and 
cleaved CCF2-AM have emission peaks of 520 nm (green) and 447 nm (blue), 
respectively, under 409 nm excitation. Fluorescent signals from both channels were 
detected using an Olympus MVX10 fluorescent microscope and quantified using ImageJ 
software. For the same virus, BlaM signal increases proportionally to amount of virus 
added (data not shown). BlaM signal also increases proportionally with amount of 
processed Env, as measured by anti-gp120 Western blot (supplemental Fig. 3-1 A).  
Therefore, viral entry signals were normalized to their corresponding gp120 
concentration for viruses bearing different amount of GFP-TM1 and HIV-1 ∆CT. Hence, 
the specific entry activity we report here represents the viral entry activity per processed 
Env. BlaM assay signal also increases proportionally to VSVg incorporation level 
(supplemental Fig. 3-1 B), so VSV-specific entry activity was also normalized to VSVg 
concentration.  
Similarly, a varying amount of pMM310 was used during transfection to create a 
series of viruses bearing titrating amount of BlaM-Vpr. 2-fold variation of BlaM 
incorporation level only slightly changed BlaM assay signal (supplemental Fig. 3-1 C). 
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Since anti-BlaM Western blots showed less than 2-fold variation in BlaM incorporation 
levels for all our GFP-TM1 titrating viruses (data not shown), BlaM incorporation level 
has not been considered during normalization. 
To investigate whether we can compare the entry activity of viruses from different 
batches, normalized entry activities of ∆CT viruses without GFP-TM1 were measured 
and found to be very similar between different batches (supplemental Fig. 3-2). Therefore, 
the entry activity of viruses is reported as relative value to that of ∆CT virus within one 
series.  
Triton X-100 (TX100) treatment 
TX100 treatment of HIV-1 particles was performed as described previously (6). 
Briefly, virus-containing supernatant was first concentrated using sucrose cushion method 
as described above. The pellet was then resuspended into 0.5% TX100 in 1 X TNE buffer, 
and incubated at 4°C for 30 min before centrifugation in a Beckman TLA-55 rotor at 
45,000 rpm for 30 min. After centrifugation, the pellet was resuspended with SDS-PAGE 
reducing sample buffer and resolved by SDS-PAGE. WB was developed to detect 
proteins of interest. 
Results 
CT alone is sufficient to regulate immature viral particle stiffness 
As previously reported (3, 13), HIV-1 Env, specifically the CT domain, is necessary 
for maintaining stiff viral particles. To discern whether CT alone can stiffen the viral 
particles, we first deleted the entire Env ectodomain (all of gp120 and most of gp41), 
leaving the gp41 TM and CT. This construct was poorly incorporated into virions (data 
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not shown). Introduction of a trimerization domain to replace the ectodomian did not 
improve incorporation (data not shown). Next, we used GFP to replace the ectodomain 
leaving TM and CT intact (GFP-TM1). GFP-TM1 incorporates into virions efficiently 
(data not shown).  
Increasing WT Env incorporation gradually increases viral particle stiffness (Fig. 3-1 
A). To investigate whether GFP-TM1 can stiffen the viral particles similarly to WT Env, 
we generated immature particles with escalating amounts of GFP-TM1. GFP-TM1 
incorporation level, measured by anti-CT western blot (WB), was normalized to Gag 
level and reported as a CT:Gag ratio. Increasing GFP-TM1 incorporation progressively 
stiffens immature particles to or beyond the WT immature level (Fig. 3-1 B). These data 
show that CT alone is sufficient to stiffen the immature viral particles in a similar manner 
to WT Env.  
Particle stiffness regulates the immature HIV-1 entry 
Both stiffness and viral entry are controlled by Env. Therefore, to investigate whether 
particle stiffness directly regulates viral entry, we need to separate the stiffness and 
entry-mediating properties of WT Env. GFP-TM1 stiffens viral particles without 
introducing entry activity (due to its missing ectodomain). ∆CT Env can mediate efficient 
entry, but contributes little to particle stiffness (13). These constructs allow us to 
modulate stiffness to determine its effect on viral entry activity. 
We cotransfected varying amounts of GFP-TM1 plasmid (to modulate stiffness) and a 
fixed amount of ∆CT Env (to provide entry activity) together with an immature ∆Env 
HIV genome. WB was used to quantify CT and ∆CT Env (represented by gp120) 
incorporation levels. Coexpression with ∆CT mildly increases GFP-TM1 incorporation 
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level relative to GFP-TM1 alone (supplemental Fig. 3-3). As with GFP-TM1 alone, 
increasing GFP-TM1 incorporation in the presence of ∆CT Env gradually increases 
immature particle stiffness (Fig. 3-2 A).  
As previously reported, Env with intact CT has minimal effects on mature particle 
stiffness (13). Therefore, as a control, the same series of mature HIV-1 particles with 
coexpression of GFP-TM1 and ∆CT Env was produced as described for immature ones. 
AFM measurement confirmed that CT incorporation does not stiffen the mature virions 
(Fig. 3-2 A). Therefore, the mature series isolates effects of GFP-TM1 incorporation on 
viral entry independent of changing particle stiffness.  
As shown in Fig. 3-2 B, increasing GFP-TM1 incorporation greatly impairs viral entry 
activity in immature ∆CT particles, while causing only modest reduction in the 
corresponding mature particles. This result, together with the observation that GFP-TM1 
only stiffens the ∆CT viral particles in the immature state, strongly suggests that 
GFP-TM1 incorporation affects viral entry activity by changing particle stiffness.  
Besides viral entry activity, we also observed that increasing GFP-TM1 incorporation 
reduces viral yield and gp160 processing (protease cleavage of gp160 to gp120 and gp41) 
(supplemental Fig. 3-4 A, B). Since gp160 processing is required for HIV-1 entry (7), this 
change could provide another explanation for GFP-TM1’s effect on viral entry. However, 
gp160 processing declines similarly in both the immature and mature states, suggesting 
that the immature-specific changes in entry activity are not due to changes in gp160 
processing (supplemental Fig. 3-4 B), although these changes may contribute to the 
modest decrease in mature particle entry activity. Nevertheless, poor gp160 processing 
does hamper the quantification of gp120 incorporation level and thus the entry activity 
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for viruses with high GFP-TM1 incorporation. As a result, normalized entry activity for 
viruses with 200% GFP-TM1 plasmid input could not be calculated. 
In all of the above studies, we used HXB2, a commonly studied CXCR4-tropic 
laboratory HIV-1 strain (9, 13). Next we investigated whether our conclusion also applies 
for JRFL, a primary CCR5-tropic strain. We coexpressed GFP-TM1 with JRFL ∆CT Env 
on mature or immature virions. An immature-specific loss of viral entry activity was 
observed with increasing GFP-TM1 incorporation, as seen with HXB2 ∆CT Env 
(supplemental Fig. 3-5). Intriguingly, in contrast to HXB2 ∆CT, increasing GFP-TM1 
incorporation reduces JRFL ∆CT Env incorporation but not gp160 processing (data not 
shown). This observation further suggests that neither incorporation nor processing of 
Env contributes significantly to the immature-specific effect on viral entry induced by 
GFP-TM1 incorporation. 
Particle stiffness regulates viral entry of VSVg pseudovirions 
HIV-1 is generally thought to enter target cells at the plasma membrane, though a 
recent report suggests endocytosis as an entry route (24). VSV, as a member of the 
Rhabdoviridae family, is unrelated to HIV-1 and is known to enter target cells via 
endocytosis mediated by its Env, VSVg (24-26). Compared to HIV-1 Env, VSVg 
incorporates at much higher levels, requires no protease cleavage to mediate entry and is 
unlikely to interact with GFP-TM1. Investigating the effect of GFP-TM1 incorporation 
on entry activity of VSVg pseudovirions therefore provides an independent test of the 
relationship between viral particle stiffness and entry.  
As with HIV-1 ∆CT Env, GFP-TM1 and VSVg were coexpressed onto mature or 
immature HIV-1 virions. WB was used to quantify CT and VSVg incorporation level. 
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Increasing CT incorporation increases particle stiffness in immature viruses (Fig. 3-3 A). 
Similarly to the effect on HIV-1 entry, increasing CT incorporation greatly reduces 
VSVg-mediated entry in immature virions with much less effect on mature virions (Fig. 
3-3 B). VSVg incorporation level changes little with increasing GFP-TM1 incorporation 
(supplemental Fig. 3-6). These results further support our hypothesis that increasing 
particle stiffness induced by CT incorporation inversely regulates viral entry and shows 
that it may be a general effect regardless of viral type, entry route and Env 
incorporation/processing level.  
GFP-TM1 does not interact with viral Env 
An important assumption of our study is that GFP-TM1 incorporation does not affect 
viral entry mediated by ∆CT Env or VSVg except by changing particle stiffness. As 
discussed earlier, GFP-TM1 cannot mediate viral entry itself, and loss of the ectodomain 
prevents trimer formation between GFP-TM1 and ∆CT Env. Nevertheless, there is still 
the possibility that GFP-TM1 physically interacts with ∆CT Env or VSVg.  
To rule out this possibility fully, we used a nonionic detergent, Triton X-100 (TX100), 
to dissociate Env from the immature Gag shell. Under Triton X-100 treatment, WT Env 
associates with the Gag shell due to the CT-Gag interaction, while truncation of CT 
causes Env dissociation from the Gag shell (5, 6). Treating immature virions bearing both 
GFP-TM1 and JRFL ∆CT Env with TX100, we observed that GFP-TM1 remains 
associated with the Gag shell while almost all JRFL ∆CT Env dissociates (Fig. 3-4). This 
result suggests that there is no specific interaction between GFP-TM1 and ∆CT Env to 
keep ∆CT Env associated with the Gag shell. A similar result was observed for HXB2 
∆CT or VSVg pseudovirions expressing GFP-TM1 (data not shown). These data suggest 
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that GFP-TM1 does not interact with coexpressed viral Env. 
Mild reduction of mature viral entry is likely due to overexpression of  
exogenous protein on the viral membrane 
Although relatively immature-specific, GFP-TM1 does cause modest loss of viral 
entry activity in the mature state as shown above. We hypothesize that this reduction is 
due to overexpression of exogeneous protein (i.e. GFP-TM1) on the viral membrane. To 
test this hypothesis, we employ another membrane protein, PLAP (human placental 
alkaline phosphatase), to see whether overexpression of PLAP will cause similar modest 
reduction of viral entry. PLAP is a cell surface, glycosylphosphatidylinositol anchored 
protein, and does not normally exist on the lymphoid cell surface (27). As with GFP-TM1, 
we cotransfected ∆CT Env (HXB2 strain) with titrating PLAP plasmid levels to produce 
immature and mature HIV-1 virions. Increasing PLAP incorporation induces modest 
reduction of viral entry in both mature and immature state, similar to the effect of 
GFP-TM1 incorporation on mature viral entry (supplemental Fig. 3-7). Therefore, mild 
reduction of mature viral entry activity is, at least partially, due to the overexpression of 
exogenous proteins on the viral surface. 
Discussion 
In this study, we aimed to test whether HIV-1 employs particle stiffness as a novel 
regulatory mechanism for viral entry. We showed that increasing particle stiffness reduces 
viral entry activity in two HIV-1 strains and the unrelated VSV. Regulation of particle 
stiffness (e.g. by interfering with the stiffness switch during viral maturation), may 
represent a novel inhibitory strategy for HIV-1 entry. To achieve this goal, it is important 
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next to understand the mechanism by which viral particle stiffness is regulated. 
Gag is the major structural protein of viral particles, and we speculate that the stiffness 
switch during HIV-1 maturation originates from the change of the Gag shell organization. 
In the immature state, the overall structure of the Gag shell is considered to be maintained 
mainly by three layers of interaction: NC-RNA interaction in the center, CA-CA 
multerization in the middle, and MA-membrane interaction (28-30). These interactions 
are greatly altered by PR cleavage. Besides the obvious morphological change, the CA 
layer transits from a tightly packed hexagonal arrangement (interring distance ~65-80 Å) 
in the immature state to a loosely packed form (interring distance ~95-110 Å) in the 
mature state (31, 32). MA relies on its N-terminal myristoyl group for membrane binding, 
and separation of downstream Gag components from MA was shown to partially bury its 
myristoyl group, which destabilizes the membrane binding and oligomer structure of MA 
(29, 33). A series of Gag mutants in which PR cleavage sites are selectively mutated will 
be employed to address the important layer(s) of interaction for particle stiffness (14).  
To address how CT regulates particle stiffness, we will employ truncation mutagenesis 
to identify the important CT subdomain for immature particle stiffness. Meanwhile, 
current estimates of the number of HIV-1 Env spikes present on the viral surface are very 
low (~10 trimers per virion), compared to up to 5,000 Gag molecules in the immature 
virion Gag shell (34-37). An interesting mechanical question is how so few CT domains 
can dramatically alter a global property, like particle stiffness, in ~100 nm particles. We 
propose two potential models: first, CT functions during assembly to affect the initial 
formation of Gag shell in a templating role (analogous to seeding a crystal); second, CT 
functions via its interaction with Gag to stabilize the whole Gag shell. To distinguish 
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these two models, the timing of when CT functions to regulate particle stiffness needs to 
be identified. Waheed et al. previously reported an Env mutant in which a new HIV-1 
protease cleavage site was created at the N-terminus of CT (38). Using this Env mutant, 
one could artificially control when CT is cleaved, and then identify the stage during 
which CT presence is critical to regulate particle stiffness.  
Moreover, mature HIV-1 bearing this mutant is resistant to inhibition of viral entry by 
a cholesterol-binding compound, AME (38). HIV-1 virions are enriched in cholesterol as 
a consequence of their budding from lipid rafts (39, 40). This observation raises the 
question whether lipid membrane components, especially cholestoral, are also important 
for particle stiffness. It is therefore tempting to speculate that AME may inhibit viral 
entry by stiffening mature particles, and AME resistance might emerge by severing of the 
link between Env CT and Gag (via CT truncation). AFM measurement of AME-bound 
mature HIV-1 and those depleted of cholesterol will help us address this possibility.  
Ultimately, structural studies of the Gag/CT interaction will be required to reveal how 
CT affects the overall Gag shell organization. Studies on other lentiviruses will show us 
whether the stiffness switch is general phenomenon during lentiviral maturation. A more 
detailed mechanistic and functional understanding of viral particle stiffness may enable 



























































Fig 3-1. CT is sufficient to regulate immature HIV-1 particle stiffness. 
  
Different amounts of WT Env (A) or GFP-TM1 (B) were incorporated into immature 
HIV-1, and the particle stiffness of these viruses was measured using AFM as 
described in Materials and Methods. Anti-CT and anti-CA antibodies were used in 
WB to detect CT-containing proteins (WT Env or GFP-TM1) and Gag, respectively. 
GFP-TM1 or WT Env incorporation levels per virion were calculated in the resulting 
viruses as CT:Gag ratios. Error bars indicate the stand error of the mean (SEM).  
 
(A). Increasing Env levels stiffen immature HIV-1. Viruses bearding different amount 
of WT Env are shown (orange diamond). X-axis values represent the Env 
incorporation levels of viruses normalized to that of virus with 100% Env plasmid 
input, and Y-axis values represent viral particle stiffness. The relationship between 
Env incorporation levels and particle stiffness is fit into a linear equation as shown in 
the figure. 
(B). Increasing GFP-TM1 levels stiffen immature HIV-1. Viruses bearing different 
amounts of GFP-TM1 (orange diamond) are shown together with immature WT HIV 
(blue diamond). X-axis values represent the CT (representing GFP-TM1) 
incorporation levels normalized to that of immature WT, and Y-axis values represent 
particle stiffness. The relationship between CT incorporation levels and particle 





















































Fig 3-2. Particle stiffness regulates immature HIV-1 entry.  
 
Different amounts of GFP-TM1 were incorporated into immature or mature HIV-1 
bearing ∆CT Env (HXB2). Anti-CT, anti-CA and anti-gp120 antibodies were used 
in WB to detect CT-containing proteins (GFP-TM1 or WT Env), Gag and ∆CT 
Env, respectively. As with Figure 3-1, GFP-TM1 amount per virion is represented 
by CT incorporation level as CT:Gag ratio. The gp120 amount represents all the 
Env capable of viral entry (∆CT or WT Env). BlaM assay signals were normalized 
by gp120 concentration (gp120 per ml) for each virus to obtain its entry ability per 
Env. Error bars indicate the SEM.  
 
(A). GFP-TM1 stiffens immature HIV-1 when coexpressed with ∆CT Env. 
Immature (orange dash) viruses bearing different amounts of GFP-TM1 are shown 
together with immature WT (blue diamond). X-axis values represent CT 
incorporation levels normalized to that of virus with 100% GFP-TM1 plasmid 
input. Y-axis values represent the stiffness values.  
(B). GFP-TM1 specifically reduces immature viral entry. Immature (orange dash) 
or mature (blue solid) viruses bearing different amounts of GFP-TM1 are shown 
together with immature (orange solid diamond) or mature (blue solid circle) WT 
viruses. X-axis shows CT incorporation levels normalized to those of the 
corresponding mature or immature viruses with 100% GFP-TM1 plasmid input. 
Y-axis shows the viral entry activities per Env normalized to those of the 






















































Fig 3-3. Particle stiffness regulates immature entry mediated by VSVg. 
 
Different amounts of GFP-TM1 were incorporated into immature or mature HIV-1 
bearing VSVg. GFP-TM1 levels per virion were determined as with Figure 3-2. 
Anti-VSVg antibody was used in WB to detect VSVg, and quantify VSVg 
concentration (VSVg per ml). BlaM assay signals were normalized by VSVg 
concentration for each virus to obtain its entry activity per VSVg. Error bars 
indicate the SEM. 
 
(A). GFP-TM1 stiffens immature HIV-1 when coexpressed with VSVg. Immature 
HIV-1 bearing different amounts of GFP-TM1 are shown (orange empty 
diamonds). X-axis values represent the CT incorporation levels of viruses 
normalized to that of virus with 100% GFP-TM1 plasmid input. Y-axis shows the 
stiffness values. 
(B). GFP-TM1 specifically reduces the entry of immature viruses bearing VSVg. 
Immature (orange empty diamonds) and mature (blue empty circles) HIV-1 
bearing VSVg and GFP-TM1 are shown. X-axis values represent the CT 
(GFP-TM1) incorporation levels of immature and mature viruses as with (A). 
Y-axis shows the entry activities per VSVg normalized to those of the 








































Fig 3-4. GFP-TM1 does not interact with coexpressed viral Env. 
 
Immature HIV-1 bearing both GFP-TM1 and JRFL ∆CT Env was treated with or 
without 0.5% TX100 as described in Materials and Methods. As for no TX100 
control, the viruses were resuspended in 1X TNE buffer instead. Gag, GFP-TM1 
and ∆CT Env were detected by WB using anti-CA, anti-CT and anti-gp120 
antibodies, respectively.  
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Supplemental Fig 3-1. Optimization of viral entry assay (BlaM assay)  
A). gp120 represents active HIV-1 Env that is cleaved by cellular protease and 
capable of viral entry. To investigate the relationship between gp120 concentration 
and BlaM assay signal, immature viruses bearing different amounts of HIV-1 ∆CT 
Env was created and measured for their entry activities. X-axis values represent 
gp120 concentration (gp120 per ml) for each virus normalized to that of virus bearing 
100% ∆CT plasmid input. Y-axis values represent the entry signal for each virus 
normalized to that of virus bearing 100% ∆CT plasmid input. Error bars (blue) 
represent the standard error of the mean (SEM). As shown in the fitting equation, 
y-axis value is proportional to x-axis value at a slope of 1, meaning that BlaM assay 
signal increases proportionally to gp120 concentration.  
B). To investigate the relationship between VSVg concentration and BlaM assay 
signal, immature particles bearing titrating amount of VSVg was created similarly as 
immature ∆CT. X-axis values represent VSVg concentration (VSVg per ml) for each 
virus normalized to that of virus bearing 100% VSVg plasmid input. Y-axis values 
represent the entry signal for each virus normalized to that of virus bearing 100% 
VSVg plasmid input. Error bars indicate the SEM. The equation shows that BlaM 
assay signal also increases proportionally to VSVg concentration.  
C). To investigate the relationship between BlaM enzyme incorporation level and 
BlaM assay signal, immature ∆CT particles were created with different amounts of 
BlaM incorporated. X-axis values represent BlaM concentration for each virus 
normalized to that of immature ∆CT with usual BlaM plasmid input. Y-axis values 
represent the BlaM assay signal for each virus normalized to that of virus with usual 
BlaM plamsid input. Error bars indicate the SEM. 2-fold variation of BlaM 






























Supplemental Fig 3-2. ∆CT viruses from different batches display similar 
entry activity. 
Immature ∆CT viruses from different batches (generated in different days) were 
analyzed for their gp120 concentration (gp120 per ml) using anti-gp120 antibody 
on the same WB and their entry activities in the same BlaM assay. X-axis 
represents ∆CT viruses from different days, and Y-axis values represent their viral 























Supplemental Fig 3-3. ∆CT slightly increases GFP-TM1 incorporation level. 
Different amounts of GFP-TM1 were expressed in immature HIV-1 bearing ∆CT 
Env. 1X means 100% plamsid input amount. For 0.5X or 1X GFP-TM1, ∆CT 
plasmid input was replaced by the same amount of pCDF-BS, which is a 
mammalian-inert expressing vector used to balance plasmid input during 
transfection. Input amount of all other plasmids (i.e. genome and GFP-TM1) 
remain the same with the corresponding viruses bearing ∆CT. CT incorporation 
levels were determined as described in Figure 3-2. X-axis shows different viruses, 
and Y-axis shows their CT incorporation levels normalized to that of immature 










































Supplemental Fig 3-4. The effect of GFP-TM1 incorporation on viral yield 
and gp160 processing. 
Immature (orange) and mature (blue) HIV-1 bearing different amounts of 
GFP-TM1 and ∆CT were generated together with WT viruses. Error bars indicate 
the SEM. 
A). Viral yield. Gag was detected by anti-CA antibody and its concentration (Gag 
per ml) was quantified as described in Materials and Methods. X-axis values 
represent CT incorporation levels normalized to those of the corresponding WT 
viruses. Y-axis values represent viral yield (Gag per ml) normalized to those of the 
corresponding ∆CT viruses.  
B). gp160 processing. Processed Env (gp120) and unprocessed Env (gp160 for 
WT Env; gp140 for ∆CT Env) were detected by anti-gp120 antibody and 
quantified as described in Materials and Methods. X-axis values represent CT 
incorporation levels normalized to those of the corresponding WT viruses. Y-axis 
values represent gp160 processing efficiency for ∆CT Env (gp120:gp140 ratio) or 
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Supplemental Fig 3-5. GFP-TM1 incorporation induces an immature-specific 
reducing effect on viral entry mediated by HIV-1 JRFL ∆CT Env. 
Different amounts of GFP-TM1 were incorporated in the immature (orange 
diamond) or mature (blue circle) HIV-1 bearing JRFL ∆CT Env. Immature (orange 
solid diamond) or mature (blue solid circle) JRFL WT viruses were also generated 
as control. Their GFP-TM1 levels per virion and entry activities were measured as 
with HXB2 viruses (Figure 3-2). X-axis shows CT incorporation levels 
(representing CT-containing GFP-TM1 or WT Env) normalized to those of the 
corresponding immature or mature viruses with 100% GFP-TM1 plasmid input. 
Y-axis shows the viral entry activities per Env normalized to those of the 
corresponding immature or mature ∆CT viruses with no GFP-TM1. Error bars 
























Supplemental Fig 3-6. GFP-TM1 incorporation has little effect on VSVg 
incorporation into virions. 
Different amounts of GFP-TM1 were incorporated in immature viruses bearing 
VSVg. Anti-CA, anti-CT and anti-VSVg antibodies were used in WB to detect 
Gag, GFP-TM1 and VSVg, respectively. CT (representing GFP-TM1) and VSVg 
incorporation levels were calculated as CT:Gag and VSVg:Gag ratio, respectively. 
X-axis shows CT incorporation levels normalized to that of virus with 100% 
GFP-TM1 plasmid input, and Y-axis shows VSVg incorporation levels normalized 





















Supplemental Fig 3-7. PLAP incorporation causes mild reduction of viral 
entry activities in both mature and immature state. 
Different amounts of PLAP were incorporated in the immature (orange diamond) 
or mature (blue circle) HIV-1 particles bearing ∆CT Env. PLAP was detected by 
anti-PLAP antibody and its incorporation level was calculated as PLAP:Gag 
ratios. X-axis values represent the PLAP incorporation levels normalized to that of 
virus with 100% PLAP plasmid input, and Y-axis values represent the viral entry 
activities per Env normalized to that of virus with no PLAP input. Error bars 
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After budding out of infected cells, Human Immunodeficiency Virus type 1 (HIV-1) 
undergoes a maturation process that is required for its infectivity. During maturation, Gag, 
the major structural protein of HIV-1 particles, is cleaved by HIV-1 protease. This 
cleavage induces a significant change in viral structure. We previously discovered a 
dramatic change in viral particle stiffness during maturation, which is further attributed to 
the cytoplasmic tail (CT) domain of HIV-1 Envelope proteins (Env). Viral particle 
stiffness was later characterized as a novel regulatory level for viral entry activity. In this 
study, we aimed to identify the critical factors that regulate viral particle stiffness and 
clarify how particle stiffness is regulated. A region near the N-terminus of the CT domain 
and the integrity of Gag structural components were shown to be likely important for 
particle stiffness regulation. Using an Env mutant with cleavable CT, we obtained 
preliminary data about the timing of CT’s regulation of particle stiffness. Our studies 
might reveal the nature of viral particle stiffness and its regulation mechanism.  
Introduction 
During the viral lifecycle, several potentially conflicting demands must be met, 
including spontaneous assembly during budding, durability in the extracellular 
environment, efficient membrane fusion and disassembly after entry into a target cell (4). 
Therefore, it is reasonable to speculate that the virus may have different physical 
properties at distinct phases of its lifecycle. Although much progress has been made in 
understanding the morphology and molecular machinery of viruses, studies of viral 
physical properties have been technically challenging and largely neglected until recent 
studies of particle stiffness using atomic force microscopy (AFM) in several viruses (2, 4, 
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5). Of these, the biggest stiffness change occurs during the maturation process for human 
immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS (Acquired 
Immunodeficiency Syndrome) (2).  
HIV-1, along with almost all other retroviruses (except spumaviruses), undergoes a 
maturation process required for its infectivity (6). Nascent HIV-1 buds out of infected 
cells as immature virions, and Gag is its major structural protein. The organization of Gag 
domains is shown in Fig. 4-1 A. Electron microscopy (EM) imaging has long been used 
to visualize the morphology of viral particles (Fig. 4-1 B). In the immature state, Gag 
forms a thick spherical protein shell (~17-19 nm) underneath the viral membrane 
surrounding an electron-lucent center (7). Maturation is induced by HIV-1 protease (PR) 
cleavage of Gag into several products, including three structural proteins, MA (forming 
the matrix), CA (forming the capsid) and NC (forming the nucleocapsid). After 
maturation, only MA remains associated with the viral membrane forming a thin matrix 
layer (~5 nm), while CA forms an electron-dense, conical capsid core housing the viral 
genome and associated proteins (7). Consistent with this striking morphological change, 
we observed using AFM that immature HIV-1 is ~14-fold stiffer than mature HIV-1, a 
dramatic change that we dubbed the “stiffness switch” (2).  
Considering the essential role of Gag in viral structure, it is reasonable to speculate 
that the stiffness switch is due to reorganization of the Gag shell. To form a single 
immature HIV-1 particle, up to 5,000 Gag molecules polymerize at the plasma membrane 
(8). Gag preferentially assembles at specific membrane microdomains enriched with 
sphingolipids and cholesterol (lipid rafts) (9). Hence, the viral membrane, which is 
derived from assembly sites of host cells, is similarly enriched. Expression of Gag alone 
83
is sufficient to generate virus-like particles without other viral proteins or the genome 
(10-12). MA mainly functions to target Gag to the assembly sites at the plasma 
membrane, while it is largely dispensable for Gag-Gag interactions (13-15). CA is the 
major driving force for Gag polymerization and has been shown by EM to form a 
hexagonal array in the immature state (13, 16, 17). Structural studies show that the 
hexagonal arrangement of CA might change from a tight packing form (~65-80 Å 
hexamer-to-hexamer distance (8, 16, 18)) to a loosely packed state (~95-110 Å hexamer-
to-hexamer distance (19, 20)) during maturation. NC mainly functions to bind the viral 
RNA genome and direct its incorporation into virions (14). Although they do not follow 
the regular hexagonal lattice symmetry, both MA and NC are thought to help initiate and 
stabilize Gag assembly, probably via their lipid and RNA interactions (21, 22). 
Additionally, Gag contains two spacer peptides, p1 and p2 (or SP2 and SP1, respectively), 
whose function is relatively unknown. At the C-terminus of Gag, p6 is a Pro-rich domain 
that interacts with host ESCRT complexes to facilitate viral budding (23-25). Deletion of 
p6 does not change the organization and thickness of Gag shell in immature HIV-1 (26).  
A rather surprising regulator for viral physical properties is the HIV-1 envelope (Env) 
protein. Env is initially synthesized as a precursor protein, gp160. In the Golgi complex, 
gp160 is further cleaved by a cellular protease, furin, into gp120 and gp41 (27, 28). With 
a transmembrane domain, gp41 anchors the whole Env complex in the membrane, and 
gp120 interacts noncovalently with gp41 on the viral surface. HIV-1 together with other 
lentiviruses has a long cytoplamic tail on gp41 compared to other retroviruses (~150 vs. 
20-30 amino acids) (29, 30). Our studies showed that Env CT is necessary and sufficient 
to stiffen the immature HIV-1 particles. It was previously shown that Murine Moloney 
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Leukemia virus (MLV), which is not a lentivirus and has a much shorter CT, has a much 
milder stiffness change (~2-fold) during its maturation (4). These studies suggest a 
correlation between CT length and the extent of stiffness change. Moreover, HIV-1 
contains much less Env  (~7-14 trimers per particle (31)) compared to Gag (up to 5,000 
copies per particle). An interesting mechanical question is how so few CT can regulate 
the stiffness of the whole viral particle.  
Although there is no detailed structural information about CT, several important 
functional domains of CT have been identified (Fig. 4-3 A): three lentivirus lytic peptides 
(LLP-1, LLP-2 and LLP-3), which are predicted to be amphipathic -helixes and have 
cytolytic effects on cell membranes (32, 33); a membrane-proximal tyrosine-based YxxL 
endocytic motif, which is responsible for rapid Env internalization (34); a C-terminal 
dileucine motif, which also mediates Env internalization through its interactions with 
cellular proteins, AP-2 and AP-1 (35, 36); and two palmitoylated Cys residues, which are 
important for Env incorporation into lipid rafts (37, 38). One interesting property of CT is 
its interaction with MA. Several lines of evidence suggest that CT binds with MA, which 
is important for Env localization and incorporation into virions (3, 9). The region 
between L751 and C762 (HXB2 numbering) has been shown to be critical for the CT-
MA interaction in the presence of nonionic detergent (3).  
Viral particle stiffness has an important role in viral entry activity. Several groups 
including ours have shown that mature HIV-1 enters target cells ~10-fold more 
efficiently than immature HIV-1 (1, 2, 39). Entry activity is inversely correlated with the 
stiffness change during maturation (2). We further showed that independently increasing 
particle stiffness greatly lowers viral entry activity, suggesting that particle stiffness has a 
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direct novel regulatory role for viral replication. We aim here to decipher how HIV-1 
particle stiffness is regulated. Mutagenesis analysis was used to isolate the important sub-
domains within CT or Gag that are important for regulating particle stiffness and viral 
entry. Furthermore, an Env mutant with cleavable CT was used to identify the timing of 
CT’s role in producing stiff particles. Preliminary results indicate that CT is only 
important for particle stiffness during viral assembly. AFM measurements are currently 
pending to confirm these conclusions. This study will improve our understanding of viral 
assembly, Env-Gag interactions, and inform the development of novel HIV-1 entry 
inhibitors.  
Methods and Materials 
Plasmids 
Plasmids were obtained or constructed as follows: ∆Env HIV-1 genome containing an 
inactivating integrase mutant (DHIV3-GFP-D116G (40), provided by V. Planelles), HIV-
1 wild type (WT) Env expression vector (pEBB-HXB2 (41), provided by B. Chen), 
vector expressing Vpr--lactamase (BlaM-Vpr) fusion protein (pMM310 (1)), and partial 
maturation Gag mutants (provided by C. Aiken (1)). Immature particles were generated 
by cloning Gag with all PR cleavage sites mutated (pNL-MA/p6, provided by C. Aiken 
(1)) into the ∆Env Int− HIV-1 genome, while mature particles were produced using a 
∆Env Int− HIV-1 genome with wild-type (WT) cleavage sites. ∆CT HXB2 Env (∆147 
(42)) was provided by E. Hunter and cloned into pEBB-HXB2. CT truncation mutants 
were obtained from C. Aiken (3), and cloned into pEBB-HXB2. Env mutant with 
cleavable CT (P203L) was obtained from E. Freed (43).  
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Viral preparation and analysis 
Pseudovirion particles were produced by cotransfection of 293T cells with ∆Env int- 
HIV-1 genome, an Env-expressing vector and pMM310. For example, to generate 
immature or mature WT virus, 2.5 g of total DNA (1.23 g genome vector, 0.819 g 
WT Env expressing vector and 0.45 g pMM310) was transfected into ~1 X 106 cells 
using 10 g polyethylenimine (PEI, Sigma). The amount of Env-expressing plasmid 
input for immature WT has been defined as 100%. Media was changed at 6 h after 
transfection to avoid PEI’s toxicity. Supernatants containing secreted viral particles were 
collected 30 h posttransfection and filtered through 0.2 m Acrodisc syringe filters (Pall). 
A series of viruses prepared on the same day is defined as one batch of viruses. 
For western blot (WB) analysis of viral concentration and Env incorporation level, 
virus supernatants were purified by centrifugation through a sucrose cushion (20% 
sucrose in 1 X TNE buffer: 0.1 M NaCl, 1 mM EDTA, 10 mM Tris, pH 7.6) at 20,000 X 
g for 90 min at 4°C. The pellet was resuspended in SDS-PAGE reducing sample buffer 
and resolved by SDS-PAGE. WB was developed using rabbit polyclonal anti-CA 
(provided by W. Sundquist), mouse monoclonal anti-gp41 Chessie 8 antibody 
(supernatant from Chessie 8 hybridoma provided by NIH AIDS Research and Reference 
Reagent Program, ARRRP), sheep polyclonal anti-gp120 (contributed by M. Phelan, 
ARRRP) and rabbit polyclonal anti-BlaM (Chemicon/Millpore). Blots were quantiﬁed 
using Li-Cor’s Odyssey scanner.  
Viral entry assay 
The viral entry assay was performed as described (2). Briefly, HIV-1 particles mixed 
with DEAE-Dextran (4 g/ml) were added onto HOS-CD4-CXCR4 cells (provided by B. 
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Chen), followed by centrifugation at 1,800 X g for 30 min at 4°C and incubation at 37°C 
for 2 h. After removal of unbound viruses, 1 M CCF2-AM solution (-lactamase 
substrate, Invitrogen) was incubated with cells at 13°C for 17 h. Uncleaved and cleaved 
CCF2-AM have emission peaks of 520 nm (green) and 447 nm (blue), respectively, 
under 409 nm excitation. Fluorescent signals from both channels were detected using an 
Olympus MVX10 fluorescent microscope and quantified using ImageJ software (NIH). 
Viral entry activity is calculated as described in Chapter 3.  
Triton X-100 (TX100) treatment 
TX100 treatment of HIV-1 particles was performed as described previously (3). 
Briefly, supernatant containing viruses was first concentrated using the sucrose cushion 
method as described above. The pellet was resuspended in 0.5% TX100 in 1 X TNE 
buffer and incubated at 4°C for 30 min before centrifugation in a Beckman TLA-55 rotor 
at 45,000 rpm for 30 min. After centrifugation, the pellet was resuspended in SDS-PAGE 
reducing sample buffer and resolved by SDS-PAGE.  
DTT recovery of PR activity 
When generating immature HIV-1 bearing Env mutant P203L, transfection was 
conducted as described above and 1 M PR inhibitor (indinavir, contributed by ARRRP) 
was added during the media change 6 h after transfection. Cells were grown in the 
presence of indinavir until viral supernatant collection. The removal of PR inhibitor and 
the recovery of PR activity were performed as described previously (44). Briefly, virus-
containing supernatant was centrifuged onto an OptiPrep cushion at 4°C, 21,000 X g for 
90 min, immediately followed by removing ~90% of the supernatant upper layer. The 
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remaining supernatant was collected and DTT was added to a final concentration of 1 
mM. After 1 h incubation at room temperature, the supernatant was centrifuged again 
onto an OptiPrep cushion as above, and ~90% of the upper layer supernatant was 
discarded. The rest of the solution was recovered, adjusted to pH~6.0 and incubated at 
37°C for 20 h to allow the reactivated PR to cleave Gag and CT.  
Results 
Structural integrity of Gag is important to suppress immature entry 
The structure of immature HIV-1 is mainly composed of a Gag shell, which contains 
thousands of Gag molecules tethered together by interactions throughout the whole 
polyprotein. To isolate the most important layer of interactions for particle stiffness, we 
employed a series of partial maturation Gag mutants, in which selective PR cleavage sites 
are mutated (Fig. 4-2 A) (1). Using these mutants, we generated viral particles having 
different Gag layer thickness ranging from mature (thinnest) to immature (thickest). For 
example, in MA/CA all other Gag domains are cleaved from MA except CA, since the 
PR cleavage site between MA and CA is mutated. These mutants were coexpressed with 
WT HIV-1 Env and their entry activities were measured (Fig. 4-2 B). MA/CA and 
MA/p2 retain similar entry activities to WT mature HIV-1 (pNL4-3). In contrast, the 
entry activity of MA/NC drops to near the level of immature HIV-1 (MA/p6). This result 
suggests that any cleavage between MA, CA, p2 and NC releases the inhibitory effect of 
immature particles on viral entry. In CA6, Gag domains from CA through p6 remain 
intact, but dissociated from MA. This mutant also showed similar entry activity to mature 
virions, further supporting the idea that HIV-1 requires the integrity of all Gag structural 
domains to suppress viral entry in the immature state. AFM measurement of these viruses 
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is pending and will determine if viral particle stiffness is affected as predicted by the 
entry data (high stiffness causing low entry activity).  
Important CT regions for regulating immature viral entry 
To isolate important CT regions for regulating particle stiffness and viral entry, we 
employed a series of CT truncation and point mutants (Fig. 4-3 A) (3). The truncation 
mutants are named after the number of residues removed from CT’s C-terminus. 
Immature HIV-1 particles bearing these mutants were generated and their entry activities 
were measured (Fig. 4-3 B). When 104 or more residues were deleted from the C-
terminus of CT, the immature virions showed robust viral entry that is similar to 
immature ∆CT. Inclusion of more C-terminal residues decreases viral entry activity with 
the biggest drop occurring between CT104 and CT93. This result suggests that the region 
between L751 and C762 (HXB2 numbering) is important to suppress the immature viral 
entry. This conclusion differs from a previous report, which claimed that the C-terminal 
28 residues of CT are important to suppress immature viral entry (3).  
To investigate the importance of the CT-Gag interaction for viral entry and particle 
stiffness, we employed a nonionic detergent, Triton X-100 (TX100), to treat immature 
HIV-1 bearing different CT truncation mutations. In agreement with a previous report (3), 
we found that the region from L751 to C762 is important for Env-Gag association in the 
presence of TX100 (Fig. 4-4). This result builds up a correlation between the Env-Gag 
interaction and immature viral entry, and likely viral particle stiffness. Particle stiffness 




Timing of CT’s regulation of viral particle stiffness and entry 
We previously proposed two models for how CT might regulate viral particle stiffness: 
(1) CT functions as a templating seed during Gag assembly to affect the initial formation 
of Gag shell; (2) CT stabilizes the stiff Gag shell via its interaction with MA. To 
distinguish these two models, it is important to identify whether CT regulates particle 
stiffness during or after viral assembly. An Env mutant (P203L) was previously reported 
in which a novel PR cleavage site is created at the N-terminus of CT (43). Using this Env 
mutant, we performed the following experiments to specifically cleave CT off Env after 
viral budding (Fig. 4-5). In the presence of a PR inhibitor, indinavir, immature virions 
bearing this Env mutant still contain intact CT, showing that PR is inactive. The stiffness 
of these virions should be similar to that of immature WT HIV-1. Irreversible inactivation 
of PR by PI was shown to be due to oxidization of Cys in PR to form a disulfide bond, 
but recovery of PR activity is possible by treatment with a reducing reagent, such as DTT 
(44). Using a similar method, PR activity was recovered after viral budding, resulting in 
almost all CT being cleaved off Env by reactivated PR. Using this construct, we created 
immature viruses in which CT is present during assembly but later cleaved after budding.  
The DTT treatment itself impairs viral entry activity. Immature WT HIV-1 had lower 
entry activity after DTT treatment compared to virions without DTT treatment (data not 
shown). Therefore, immature P203L and WT HIV-1 were produced in parallel in the 
presence of PI and their PR activities were recovered as described in Materials and 
Methods. The recovery protocol caused similar reduction for the viral entry activities of 
immature WT and P203L viruses (before vs. after DTT recovery) (data not shown). This 
result suggests that immature viruses with CT cleaved after budding have similar entry 
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activity with immature WT, indicating that CT may only function during viral assembly 
to regulate the viral particle stiffness. AFM measurements are pending.  
Discussion 
In this study, we aimed to understand the nature of viral particle stiffness and its 
regulation. First, we showed that Gag integrity from MA to NC is important to suppress 
immature viral entry, and likely viral particle stiffness. This result agrees with our 
expectation that viral particle stiffness originates from the organization of the Gag shell, 
and the stiffness switch is due to the dramatic reorganization of the Gag shell during 
maturation. The immature Gag lattice and mature capsid have been intensively studied 
using various structural methods (16, 17, 19). These studies showed that the Gag lattice 
or mature capsid is mainly composed of hexamer rings formed by CA, while MA and NC 
do not display a hexagonal arrangement. Recent studies of membrane-bound CA 
symmetry posed an interesting point on Gag assembly. Individual CA protein can form 
two forms of hexamer: one is more tightly packed like immature Gag lattice, and another 
is more loosely packed, similar to mature capsid core (45). More intact Gag including all 
structural proteins (MA, CA, p2 and NC) constrains the hexagonal arrangement to the 
tightly packing form (18), suggesting that the tight-to-loose packing might represent the 
reorganization of the Gag shell and the changes of viral structure and physical properties.  
Gag shell reorganization is not solely limited to the CA layer. MA contains an N-
terminal myristyol group that is important for membrane binding of Gag (7, 46). 
Individual MA proteins bind membrane much less efficiently than intact Gag, and 
deletion of the C-terminal domain of MA enhances membrane binding (47, 48). 
Therefore, a “myristyol switch” model has been proposed in which the myristyol group is 
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fully exposed in the immature state to enhance membrane binding, but is partially hidden 
in the mature state. A structural study has revealed the detailed repositioning of several 
residues within the myristyol group to enhance MA’s membrane binding, further 
supporting this model (49). A thermal stability study shows that myristoylated MA 
polymerizes more stably than unmyristyolated MA (50). These results suggest that the 
maturation process, which induces the partial sequestration of MA’s myristyol group, 
may destabilize the matrix layer. Combining our result that Gag’s structural integrity is 
important for regulation of viral entry (and therefore likely particle stiffness), all the 
above data suggest that in immature virions, Gag molecules pack more tightly to form a 
rigid and stiff protein shell, and PR cleavage loosens up the packing of MA and CA 
layers to generate much softer virions that may lower the energy barrier for membrane 
fusion and uncoating.  
Why is Env CT important? Our study shows that the N-terminal CT is important for 
regulating viral entry activity, which disagrees with a previous report from the Aiken 
group. This disparity may be attributed to different measurements of viral entry. The 
Aiken report focused on the entry activity per virion, while we measure viral entry 
activity per Env. Moreover, we show that the CT-Gag interaction may be important for 
particle stiffness, and CT may not be required for stiff particles after budding, although it 
is currently a preliminary result waiting for AFM confirmation. These results suggest that 
the CT-MA interaction helps Gag overcome the energy barrier to initiate the formation of 
a tightly packed Gag shell. However, due to the overwhelming number of MA or Gag to 
CT, CT cannot maintain the organization of Gag shell during PR cleavage. An alternative 
explanation for cleavable CT data is that cleaved CT still associates with Gag to stiffen 
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the immature particles. Env constructs with additional cleavage sites within CT may help 
us rule out this possibility.   
Intracellular organelle or plasma membranes are not homogeneous but rather contain 
various lipid microdomains. As mentioned above, Gag preferably assembles at one type 
of microdomain, lipid raft(s), which is highly enriched in sphingolipids and cholesterol. 
Therefore, HIV-1’s membrane also contains relatively high amounts of sphingolipids and 
cholesterol.  The Freed group has reported that a cholesterol-binding compound, AME 
(amphotericin B methyl ester), specifically inhibits viral entry, and this inhibition is 
abolished if Env CT is truncated. This result suggests that AME may stiffen viral 
particles through its binding to viral membrane to inhibit viral entry, while softening by 
CT truncation reverses the phenotype. AFM measurement of AME-bound viral particles 























Fig 4-1. HIV-1 Gag and viral structure change during maturation.  
(A). Schematic representation of HIV-1 Gag domains.  
(B). Schematic models (top) and EM images (bottom) of HIV-1 immature 
and mature virions. Viral lipid membrane is labeled in purple and HIV Env 
trimer spikes are in brown. HIV-1 Env does not undergo proteolytic 
processing during maturation. For simplicity, the unstructrual Gag proteins 
(p1, p2 and p6) are not included in the virion model. The models are 









Fig 4-2. Mapping Gag domains important for regulating immature viral 
entry.  
(A). Schematic representation of partial maturation Gag mutants. The red 
crossing means that the PR cleavage site at that location is mutated. The figure is 
reprinted with permission from (1). (B). The effect of different Gag processing 
on viral entry. X-axis shows different Gag mutants and Y-axis values represent 
their viral entry activities normalized to incorporated Env amount and that of 










Fig 4-3. Mapping CT sub-domains important for regulating viral entry.  
(A). Schematic representation of putative CT sub-domains, and CT truncation or 
point mutation mutants. The figure is reprinted with permission from (3). (B). 
The effect of CT truncation on immature viral entry activity. X-axis shows the 
CT mutants and Y-axis values represent their viral entry activities normalized to 








Fig 4-4. Isolation of CT region important for CT-Gag interaction.  
The CT mutants listed on the X-axis were expressed on immature HIV 
particles, which were treated with (blue bar) or without (red bar) 0.5% TX100. 

















Fig 4-5. CT cleavage by reactivated PR.  
Env mutant P203L was coexpressed with MA/NC Gag mutant. Gag and CT 
were detected by anti-CA (top panel) and anti-CT (bottom panel) antibodies, 
respectively. In the presence of PI (1 M indinavir), CT is associated with 
the rest of Env (higher MW band). After removal of PI and reactivation of 
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The human immunodeficiency virus envelope glycoprotein (Env) is com-
posed of surface (gp120) and transmembrane (gp41) subunits, which are
noncovalently associated on the viral surface. Human immunodeficiency
virus Env mediates viral entry after undergoing a complex series of con-
formational changes induced by interaction with cellular CD4 and a
chemokine coreceptor. These changes propagate from gp120 to gp41 via the
gp120–gp41 interface, ultimately exposing gp41 and allowing it to form the
trimer-of-hairpins structure that provides the driving force for membrane
fusion. Key unresolved questions about the gp120–gp41 interface include
the specific regions of gp41 and gp120 involved, the mechanism by which
receptor and coreceptor-binding-induced conformational changes in gp120
are communicated to gp41, how trimer-of-hairpins formation is prevented
in the prefusogenic gp120–gp41 complex, and, ultimately, the structure of
the prefusion gp120–gp41 complex. Here, we develop a biochemical model
system that mimics a key portion of the gp120–gp41 interface in the pre-
fusogenic state. We find that a gp41 fragment containing the disulfide bond
loop and C-peptide region binds primarily to the gp120 C5 region and that
this interaction is incompatible with trimer-of-hairpins formation. Based on
these data, we propose that in prefusogenic Env, gp120 sequesters the gp41
C-peptide region away from the N-trimer region, preventing trimer-of-
hairpins formation until coreceptor binding disrupts this interface. This
model system is a valuable tool for studying the gp120–gp41 complex, con-
formational changes induced by CD4 and coreceptor binding, and the
mechanism of membrane fusion.
© 2007 Elsevier Ltd. All rights reserved.
Edited by M. F. Summers Keywords: HIV; gp120; gp41; viral entry
Introduction
Human immunodeficiency virus (HIV) enters
target cells by fusion of the virus and cell mem-
branes, mediated by the viral envelope glycoprotein
(Env). HIV Env is initially synthesized as gp160,
which is cleaved by cellular proteases into trans-
membrane (gp41) and surface (gp120) subunits.
After cleavage, gp41 and gp120 remain noncova-
lently associated and form trimeric spikes on the
surface of virions (reviewed byWyatt and Sodroski1
and Eckert and Kim2) (Fig. 1a). gp120 recognizes
appropriate target cells by interacting with CD4 and
a coreceptor (typically CXCR4 or CCR5). The initial
binding of CD4 induces a major conformational
change in gp120 that creates and exposes the
coreceptor-binding site.1,3–5 Subsequent coreceptor
binding induces additional poorly characterized
conformational changes in the gp120–gp41 complex
that are required for membrane fusion and viral
entry.
Membrane fusion is directly mediated by gp41,
which contains an ectodomain (ED), a transmem-
brane domain (TM), and a long cytoplasmic tail
domain (CT) (Fig. 1b). The ED can be further
divided into several regions, listed from N- to
C-terminus: hydrophobic fusion peptide (FP),
N-peptide region, disulfide bond loop (DSL), C-pep-
tide region, and membrane proximal domain.
Currently, only the postfusion structure of gp41 is
*Corresponding author. E-mail address:
kay@biochem.utah.edu.
Abbreviations used: HIV, human immunodeficiency
virus; ED, ectodomain; TM, transmembrane domain; CT,
cytoplasmic tail domain; FP, fusion peptide; DSL, disulfide
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known. In this structure, three N-peptides form a
central parallel trimeric coiled coil that is sur-
rounded by three antiparallel C-peptides, forming
a very stable six-helix bundle structure (also known
as trimer-of-hairpins).6–9 Before the formation of this
six-helix bundle, gp41 transiently adopts an ex-
tended conformation (prehairpin intermediate), in
which the N-peptide trimer (N-trimer) has formed
but the C-peptide regions have not yet associated
with it. This intermediate state of fusion is vulnerable
to inhibition by peptides that bind to the N- or
C-peptide regions (including the HIVentry inhibitor,
T20/Fuzeon).10–14
Formation of the six-helix bundle provides the
driving force for membrane fusion by bringing the
viral and cellular membranes (attached by the TM
and FP, respectively) into close apposition (reviewed
by Chan and Kim15) (Fig. 1a). gp41 stores energy for
fusion by initially separating the N- and C-peptide
regions and by preventing them from forming the
stable six-helix bundle until after CD4 and corecep-
tor engagement of gp120 triggers fusion at the
appropriate time and place. The least understood
component of the pathway is the prefusogenic
gp120–gp41 complex, which has resisted high-
resolution structural analysis. A key unanswered
question is how the gp120–gp41 interface maintains
gp41 in its metastable prefusogenic conformation
(i.e., preventing formation of the very stable trimer-
of-hairpins structure).
gp120 contains five conserved constant regions,
C1–C5, and five variable loop regions, V1–V5.16 The
most direct evidence implicating specific regions of
Env in the gp120–gp41 interface comes from SOS
Env, which contains an engineered disulfide bond
between the gp41 DSL and gp120 C5 regions. These
regions are spatially close enough to form an
intermolecular disulfide bond in the native prefuso-
genic state of Env.17 The C1 region of gp120 is also
thought to be a contributor to the gp120–gp41 inter-
face because mutations that cause gp120 “shedding”
from gp41 on the viral surface are predominantly
localized to this region, as well as C5 of gp120 and
the DSL region of gp41.18–23 However, many of these
Env mutants are also associated with poor proteo-
lytic processing, expression, or trafficking, suggest-
ing global Env misfolding in a substantial fraction
of Env rather than direct disruption of the gp120–
gp41 interface. In addition, since even a significant
fraction of wild-type (wt) Env on the viral surface is
misfolded or unprocessed,24 cell/virus-based stu-
dies do not provide clear data on the nature of the
gp120–gp41 interface in properly folded Env.
The main obstacle to a detailed understanding of
the gp120–gp41 interface has been the lack of high-
resolution structural information. Existing HIV Env
structures have been extremely informative, but
only reveal the gp41 postfusion state (six-helix
bundle)6–9 or the “core” structure of gp120 (exclud-
ing most of the variable loops and the C1/C5
regions).5,25,26 Unfortunately, all currently available
gp120 structures lack the N- and C-terminal regions
that are most likely to participate in the gp120–gp41
interface. An NMR structure of the isolated C5
region peptide has been determined using trifluor-
oethanol to induce secondary structure in the other-
Fig. 1. HIV entry model and
schematic of gp41 and gp120 frag-
ments. (a) Working model of HIV
entry. (b) Schematic of gp41 frag-
ments. gp41 consists of the ED, TM,
and CT. Constructs N-DSL49 (resi-
dues 540–666), DSL49 (residues
584–666), DSL20 (residues 584–
637), C49 (residues 618–666), C43
(residues 624–666), C20 (residues
618–637), and DSL (residues 584–
622) are shown. DSL has one intra-
molecular disulfide bond, indicated
by the dashed line between Cys598
and Cys604. All gp41 fragments
contain a C-terminal His tag. (c)
JRFL-gp120 deletion constructs.
ΔC1 (residues 33–82), ΔC5 (resi-
dues 493–511), ΔV1/V2 (residues
128–194), and ΔV3 (residues 303–
323) are indicated. For ΔC1, ΔV1/
V2, and ΔV3, the deleted loops are
substituted with GS, GAG, and GA,
respectively. Core gp120 contains
all of the deletions (ΔV1/V2/V3
andΔC1/C5). Amino acid number-
ing is based on the prototypic HXB2
gp160 sequence.
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wise disordered C5 peptide,27 but the relevance of
this structure under native conditions is not known.
Initial studies on the gp120–gp41 interaction
implicated CD4 binding as the trigger for gp120–
gp41 dissociation, since exposure to soluble CD4
(sCD4) caused “shedding” of gp120 (e.g., Sattentau
and Moore3 and Moore et al.28). However, this
conclusion has been supplanted by more recent
work showing that sCD4-induced shedding is not
physiologically relevant to the fusion pathway of
primary isolates and may be an artifact due to the
significant population of misfolded Env present on
virus and cell surfaces.2,24,29,30
In order to better define the gp120–gp41 complex
and to study its conformational changes during the
entry process, we have developed a stable biochem-
ical model system of this interface. First, we have
identified gp41 fragments that bind to gp120 and
mimic a major portion of the prefusogenic gp120–
gp41 interface. Second, using these fragments, we
have characterized the regions of gp41 and gp120
contributing to this interface. Finally, we used these
fragments to study conformational changes in gp41
affecting the gp120–gp41 interface and changes in
the complex by CD4 binding. Most interestingly, this
study suggests a mechanism for the separation of
the gp41 N- and C-peptide regions in the prefuso-
genic conformation of the gp120–gp41 complex.
This biochemical model system will also likely find
broad utility in future mechanistic and structural
studies of the gp120–gp41 interface.
Results
Identification of gp41 fragments that bind to
gp120
In this study, we employ gp120 from JRFL (a
standard primary HIV-1 isolate) for two main
reasons. First, primary isolates of HIV-1 do not suffer
from the gp120 shedding artifact seen in many
laboratory-adapted isolates in the presence of
sCD4.31 As a typical primary R5 strain, JRFL is
more likely to reflect the gp120–gp41 interaction of
clinical isolates. Second, a previously studied
C-peptide, T20, has been reported to bind in a non-
specific manner to the V3 loop of X4 strain gp120 in
the presence of sCD4, but not to R5 strain gp120.32,33
We constructed a variety of HIV-1 gp41 fragments
(named as shown in Fig. 1b) to find those that
bind to JRFL gp120 and potentially mimic the
gp120–gp41 binding interface. Importantly, to pre-
vent gp41 trimer-of-hairpins formation, we avoided
including both N- and C-peptide regions in the same
fragment. We excluded the N-peptide region from
further studies based on preliminary screening
showing that gp41 fragments containing both the
N-peptide and DSL regions did not interact with
gp120 (data not shown). Therefore, our main series
of fragments focused on the DSL and C-peptide
regions.
DSL49, DSL20, and C49 show weak binding to
gp120, which is significantly enhanced in the
presence of sCD4 (Fig. 2a and b). Both with and
without sCD4, DSL49 shows the strongest binding,
followed by DSL20 and C49, while DSL, C20, and
C43 do not show detectable binding to gp120. Thus,
the N-terminal part of the C-peptide region has a
significant role in this interaction, as shown by the
increased binding of DSL20 versus DSL and C49
versus C43. The increased binding of DSL49 com-
pared to DSL20 also suggests a contributing role of
the C-terminal part of the C-peptide region.
Fig. 2. Binding of gp41 fragments to gp120. (a) gp41
fragments were incubated with gp120 in the presence or in
the absence of untagged sCD4 and precipitated with Ni+
beads. Eluents were deglycosylated and analyzed by
nonreducing SDS-PAGE Western blot analysis with anti-
gp120 antibody. Mock lane contains gp120 without any
gp41 fragment. (b) Quantification of monomeric gp120
binding from (a). Binding percentage was normalized to
the amount of gp120 precipitated by CD4-H6 in the
absence of untagged sCD4. (c) DSL49, DSL20, and C49
incubated with gp120 in the presence or in the absence of
sCD4 and 5-helix as indicated. (d) Schematic diagram of 5-
helix binding to gp41 fragments.
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Maintaining the metastable prefusogenic gp41
conformation
For trimer-of-hairpins formation and membrane
fusion to occur at the appropriate time and place, the
N- and C-peptide regions must be prevented from
associating until after both CD4 and coreceptor have
bound to gp120. The interaction we observed
between C-peptide-containing fragments (DSL49,
DSL20, and C49) and gp120 suggests a possible
mechanism for the sequestration of the C-peptide
region from the N-peptide region. To test this idea,
we measured the interaction of our gp41 fragments
with gp120 in the presence of 5-helix. 5-Helix is an
engineered protein that binds to C-peptides with
high (subpicomolar) affinity to reconstitute the six-
helix bundle (Fig. 2d).10 The addition of 5-helix to
DSL49 or C49 dramatically decreased their interac-
tion with gp120 (Fig. 2c). In order to show that this
effect was not induced by competitive binding of
5-helix to gp120, we used glutaraldehyde cross-
linking to monitor the interaction of 5-helix and
gp120. While DSL49 made a crosslinked complex
with gp120 and sCD4, 5-helix could not (data not
shown). DSL20's interaction with gp120 was also
decreased by 5-helix, but less dramatically than for
DSL49 and C49 (Fig. 2c). This smaller decrease likely
results from DSL20's partial C-peptide sequence,
which reduces its binding affinity for 5-helix. These
results show that the six-helix bundle conformation
of gp41 is not compatible with the stable formation
of the interface between our gp41 fragments and
gp120, supporting the idea that this interface
sequesters the C-peptide region and prevents six-
helix bundle formation.
The gp120 C5 region forms the main interaction
interface with gp41 fragments
Todefine the binding site for our gp41 fragments in
gp120, we examined a series of gp120 deletion
constructs (Fig. 1c). Each deletion mutant was
incubated with DSL49 and DSL20, which show the
strongest interaction with wt gp120 (Fig. 2a and b).
First, ΔC1-gp120, ΔC5-gp120, and ΔC1/C5-gp120
were examined, since the C1 and C5 regions have
been previously suggested to participate in the
gp120–gp41 interface. In the presence of sCD4,
ΔC5 and ΔC1/C5 show significantly weakened
interactions, while ΔC1 is only slightly weakened
compared to wt gp120 (Fig. 3a and b). These results
indicate that the gp120's C5 region is critical for
DSL49 or DSL20 binding, while the C1 region is of
lesser importance.
Next, the contribution of gp120's variable loops
was examined using ΔV1/V2/V3-gp120 and core-
gp120 (ΔV1/V2/V3/C1/C5) (Fig. 3). In the absence
of sCD4, ΔV1/V2/V3-gp120 showed stronger bind-
ing than wt gp120 to DSL49 and DSL20, but core-
gp120 only showed a very weak residual interac-
tion, similar to ΔC1/C5-gp120. In the presence of
sCD4, ΔV1/V2/V3-gp120 and wt gp120 showed
similar binding to DSL20 and DSL49, while core-
gp120 only bound weakly. These results indicate
that the main variable loops of gp120 (V1/V2/V3)
are not required for the interaction with our gp41
Fig. 3. Interaction between gp41 fragments and gp120
deletion mutants or MBP-C1/C5. (a) gp120 deletion
constructs were coprecipitated with DSL49 and DSL20±
sCD4 as described in Fig. 2a. (b) Quantification of
monomeric gp120 binding from (a), normalized as in
Fig. 2b. (c) Coprecipitation of 10 μM MBP or MBP-C1/C5
with 2 μM DSL49. As a negative control, His-tagged Ub
(Ub-H6) was used. Loading control contains 1 μM MBP
and MBP-C1/C5 (corresponding to 50% of maximal
binding to 2 μM DSL49) and 2 μM DSL49 and Ub-H6
(100% of maximal binding). Proteins precipitated by Ni+
beads were analyzed by SDS-PAGE.
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fragments, in contrast to the previously reported
nonspecific T20 binding to X4 strain gp120.32,33
To confirm that the gp120 regions identified by
screening with deletion mutants bind to DSL49
specifically, we produced C5 and C1/C5 fragments
of gp120 fused to the C-terminus of maltose-binding
protein (MBP; MBP-C5 and MBP-C1/C5, respec-
tively). MBP is commonly used as a fusion partner
and aids the production, detection, and solubility of
these small peptide fragments. DSL49 showed
strong binding to MBP-C1/C5 (Fig. 3c), but did
not bind to MBP-C5 (data not shown). This
interaction was reduced by the addition of 5-helix,
as observed with binding to gp120 (Fig. 2c). As an
additional control, we observed that sCD4 had no
effect on this interaction, as expected, since MBP-
C1/C5 lacks the CD4-binding site of gp120 (data
not shown). Although C1 did not show a major role
in the interaction with DSL49 in the context of
gp120, C1 may help stabilize or solubilize the
isolated C5 fragment in the context of our MBP
construct.
Mapping the minimal determinants of gp41
fragment binding to gp120
We further dissected DSL20 to determine the
minimal fragment capable of interacting with
gp120. First, we investigated the role of the DSL
N-terminal region in gp120 binding by truncating
the N-terminus of DSL20 (Fig. 4a). Both 13- and 20-
residue deletion mutants (Δ13-DSL20 and L20,
respectively) dramatically decreased interaction
with both wt and ΔV1/V2/V3-gp120 (Fig. 4b)
compared to DSL20, indicating that the N-terminal
13 residues of DSL20 are required for this interac-
tion. Next, we tested the role of the disulfide bond in
DSL20 by mutating both Cys residues to Ser to
produce DSL20ss (Fig. 4a). DSL20 and DSL20ss
showed similar binding affinities for both wt and
ΔV1/V2/V3-gp120 (Fig. 4b), indicating that the
DSL disulfide does not play a significant role in
binding gp120.
Since the DSL disulfide is highly conserved in
all known HIV and SIV strains,8,34 it likely plays a
critical role in Env function. Previous studies have
reported that peptides from the DSL region may
bind directly to membranes.35,36 To address the
specific role of the disulfide bond in DSL, we
measured the binding of DSL20 and DSL49 to
cellular membranes. DSL49 and DSL20 both showed
significant cell surface binding by Western blot
analysis (Fig. 4c). This result was confirmed by cell
surface immunostaining, which also revealed a
punctate-binding pattern (Fig. 5). In contrast, C49
shows minimal cell surface binding (data not
shown).
To further examine the role of the DSL disulfide
bond in mediating membrane binding, we dis-
rupted the disulfide bonds using: mutagenesis
(DSL49ss and DSL20ss), reduction (DSL49-red),
and reduction with blocking by the hydrophobic
N-ethylmaleimide (NEM) and hydrophilic iodoace-
tate (Ac) to produce DSL49-NEM and DSL49-Ac,
respectively. DSL20ss, DSL49ss, and DSL49-red
bound to the cell surface much less efficiently
(Figs. 4c and 5). DSL49-Ac also bound to the cell
surface very weakly (Fig. 4d). In contrast, DSL49-
NEM displayed more cell surface binding than
DSL49ss, DSL49-Ac, and DSL49-red. These results
indicate that the DSL disulfide's hydrophobic
character is likely the most important determinant
for membrane binding, since the introduction of
more polar groups (e.g., reduced Cys, Ser, or Ac) is
more disruptive than hydrophobic substitutions
(e.g., oxidized Cys or NEM). In addition, the cell
surface binding of DSL49 and DSL20 is distinct from
their binding to gp120, which is not affected by the
mutagenesis of the DSL disulfide bond (Fig. 4b).
This conclusion is further supported by the cell
surface binding of DSL49 in the presence of 5-helix
(Fig. 4c), which actually enhances cell surface
binding, possibly due to induced helical structure
Fig. 4. Binding of DSL20 mutants to gp120 and cell
surface. (a) DSL20 mutant constructs: Δ13-DSL20 (resi-
dues 597–637), L20 (residues 605–637), and DSL20ss
(C598S and C604S). (b) DSL49, DSL20, and DSL20
mutants were incubated with gp120 in the presence of
sCD4. Mock lane contains only gp120 and sCD4. (c)
Binding of DSL49, DSL49ss, DSL20, and DSL20ss to HOS
cells. Right panel shows the effect of 5-helix addition on
cell surface binding. Bound proteins on the cell surface
were analyzed by Western blot analysis with anti-His tag
antibody. Mock lanes were prepared without addition of
gp41 fragment. (d) Binding of DSL49, DSL49ss, DSL49-
NEM, DSL49-Ac, and DSL49-red to HOS cells.
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or enhanced solubility (a similar enhancement is
seen with DSL49ss; data not shown).
Discussion
The gp120–gp41 interface has resisted detailed
biochemical and structural characterization for
several reasons, including: (1) the fragility of the
native gp41 conformation (due to its metastability
and strong tendency to adopt the postfusion six-
helix bundle structure); (2) the flexible nature of
gp120 regions participating in this interface (requir-
ing their removal for crystallography5,25,26); and (3)
lack of a detailed understanding of the residues
in gp120 and gp41 participating in this interface
(due to challenges in interpreting Env mutants in
vivo). The structural and mechanistic details of how
the gp120–gp41 interface is affected by receptor and
coreceptor binding during HIVentry are also poorly
understood. In this work, we make significant prog-
ress towards overcoming these barriers by develop-
ing a stable biochemical system that partially
mimics the gp120–gp41 interface. Using this system,
we strengthen previous findings that the gp120 C5
and gp41 DSL regions contribute to the gp120–gp41
interface. The value of this biochemical system is
demonstrated by our new findings that the C-pep-
tide region makes key contact with the gp120 C5
region and that this interaction may be responsible
for sequestering the C-peptide region and for pre-
venting six-helix bundle formation in the prefuso-
genic state.
Role of the V1/V2 loops in the gp120–gp41
interface
Most interactions between our gp41 fragments
and gp120 are strengthened by sCD4 binding. This
result may seem surprising in the context of earlier
studies showing sCD4-induced shedding of gp120
in laboratory-adapted strains.3,28 However, the
impact of CD4 binding on the gp120–gp41 interac-
tion in properly folded Env from primary strains is
currently unknown. There is strong evidence that
sCD4 binding alone is insufficient to release gp120
from gp41, including the ability of HIV to enter
CD4(−) cells when sCD4 is provided in trans
(sCD4-activated fusion)40 and the existence of
CD4-independent HIV strains.41 The sCD4-induced
enhancement of binding may be explained by two
possibilities. First, unliganded monomeric gp120 is
known to have a flexible structure that is signifi-
cantly rigidified upon CD4 or antibody binding,42
which may stabilize the monomeric gp120–gp41
interface. Second, sCD4 binding also triggers spe-
cific conformational changes in monomeric gp120
that may facilitate the gp120–gp41 interaction in this
biochemical system.
To help explain the effect of sCD4 binding on the
monomeric gp120–gp41 interaction, we compared
the crystal structures of unliganded and sCD4-
bound core gp120 (ΔC1/C5/V1/V2/V3) (Fig. 6).
In the unliganded gp120 structure, the V1/V2 stem
is located near the N- and C-termini (C1 and C5
stumps), which may allow the V1/V2 loop to
occlude the C1/C5 region when the ~80 deleted
residues of V1/V2 are present. In the sCD4-bound
gp120 structure, the V1/V2 stem undergoes a dra-
matic movement away from the N- and C-terminal
regions and is now located near the V3 loop and
coreceptor-binding site.43 If the V1/V2 loop ob-
structs gp41 fragment binding in unliganded gp120,
wewould expect either sCD4 binding or V1/V2 loop
deletion to enhance gp41 fragment binding, consis-
tent with our data (see Fig. 3). In support of this idea,
deletion of the V1/V2 loop has been shown to
functionally substitute for CD4 binding in exposing
the coreceptor-binding site of the monoclonal anti-
body 17b.44
Fig. 5. Immunostaining of DSL49 and its DSL49ss on cellular membrane. DSL49 or DSL49ss was incubated with HOS-
pBABE cells and stained with rabbit anti-His6 antibody and Alexa Fluor 568 goat anti-rabbit antibody. Cells were placed
on the slide and photographed at magnifications of 40× and 100×.
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In the context of trimeric gp41 interacting with
three gp120 proteins, it is very likely that gp120 also
makes important intersubunit contacts to stabilize
the trimeric spike. Models of trimeric gp120 have
been proposed based on electron microscopy and
crystallographic data, in which the V1/V2 loop
contacts the V3 loop of a neighboring gp120 within
the trimer.5,45 If the V1/V2 loop is involved in such
an intermolecular interaction, this alternate confor-
mation would explain why the monomeric gp120–
gp41 interaction appears relatively weak in the
absence of sCD4 (in our system), but is more robust
on the virion surface. In the monomer, the V1/V2
loop appears to obscure the gp41 interface region,
but in the context of a trimer, the V1/V2 loop would
be removed from this interface by lateral contacts
with neighboring gp120s.
Conformational changes during fusion
HIV Env undergoes complex and extensive con-
formational changes upon interaction with CD4
and a coreceptor. How and when conformational
changes in gp120 are transmitted to gp41 via their
interface are important unanswered questions. For
completion of membrane fusion, the interaction
between gp41 and gp120 must be weakened to
allow formation of the six-helix bundle. Strong
evidence for this requirement is provided by SOS
Env, which can only mediate membrane fusion
when its engineered gp120–gp41 disulfide bond is
broken with a weak reducing agent.37,38 Coreceptor
binding is likely the most critical step in the fusion
pathway, since several CD4-independent Envs can
fuse, but no coreceptor-independent strains have yet
been identified.
Our biochemical results show that the C-peptide
region of gp41 maintains binding to gp120 after
sCD4 binding, but this interaction must ultimately
be dissociated to allow the formation of the trimer-
of-hairpins structure that mediates membrane
fusion. Coreceptor binding to gp120 is the most
likely remaining stimulus that can induce this
conformational change. Using the data obtained
here and in previous studies, we propose a modified
model for the gp120–gp41 interface and how this
interface responds to CD4 and coreceptor binding.
In the native (prefusogenic) state, the DSL and
C-peptide regions interact with gp120 primarily via
the C5 region. Interaction of the C-peptide region
with gp120 can sequester it and prevent the for-
mation of the six-helix bundle until coreceptor
engagement disrupts this interface and liberates
the C-peptide region (Fig. 7).
In support of this idea, a recent report by Steger
and Root shows that the C-peptide region is
accessible to inhibitors for a much shorter period
of time (in seconds) than the N-peptide region (in
minutes) during fusion.39 This observation is con-
sistent with the sequestration of the C-peptide
region by gp120 observed here. If coreceptor
binding triggers the dissociation of the C-peptide
from gp120, the short kinetic window of C-peptide
accessibility to 5-helix may reflect the time needed to
form the six-helix bundle after the C-peptide is
liberated from its interaction with gp120.
Fig. 6. CD4-induced conformational changes in gp120. Structural comparison between unliganded (left) and CD4-
bound (right) gp120. Structures are rendered from Protein Data Bank accession numbers 2BF1 and 1RZJ, respectively,5,26
using PyMol. Blue and red spheres indicate the N-terminus and the C-terminus, respectively. Yellow and green indicate
the V1/V2 stem and the V3 stem, respectively.
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Roles of the DSL region disulfide bond
The intramolecular disulfide bond in the DSL
region is highly conserved and thought to be
important for the structure and function of HIV
Env.8,34,46 Although gp41 can adopt a postfusion
six-helix bundle structure without this disulfide,8 it
is currently thought to exist in the prefusogenic gp41
structure.47 The functional role of this disulfide bond
in HIV entry has been difficult to assess because
mutations of these cysteines or intermolecular
disulfide bond formation has been shown to disrupt
Env proteolytic processing and trafficking.46,48–50
Several studies have reported that the DSL region
exhibits membrane-binding properties.35,36 Mem-
brane binding of the DSL region could provide
additional force right before membrane fusion by
bringing viral and target cell membranes more
closely together.35,51 Here, we show that the DSL
disulfide is not required for gp120 binding, but does
play a role in cell surface binding. Interestingly, the
cell surface interaction is affected by the hydro-
phobicity of the disulfide region rather than by
formation of the disulfide itself. The cell-surface-
binding properties of DSL49 are not disrupted by
six-helix bundle formation, providing additional
evidence that DSL49's cell surface and gp120
binding interactions are distinct. This result also
implies that the cell-surface-binding interaction can
be maintained late in the fusion reaction after six-
helix bundle formation. Our gp41 fragment model
system will be useful for dissecting the distinct
properties of gp120 and cell binding to study how
they relate to Env trafficking, processing, and fusion
activity.
Overcoming barriers to obtaining a
high-resolution gp120–gp41 interface structure
In contrast to the intrinsically flexible variable
loops of gp120, the flexibility of the gp120 C1 and C5
regions in monomeric gp120 is likely due to the
absence of their natural binding partner, gp41.
Binding of these regions to an appropriate gp41
fragment may stabilize these regions and allow
structural characterization of the gp120–gp41 inter-
face. Further work will be required to achieve this
goal, including optimization of fragment solubility
and complex stability, possibly via covalent linkage
(e.g., crosslinking or flexible linker).
Limitations of our biochemical system
An important caveat for interpreting these
studies is that DSL49 likely does not mimic the
entire gp120–gp41 interaction interface due to the
absence of the gp41 FP and N-peptide regions.
Biochemical studies of the FP's role in the gp120–
gp41 interface are hampered by its poor solubility
(leading to its absence in these studies). The FP
ultimately inserts into the target cell membrane,
but its status during each step of the entry
pathway is poorly understood. In preliminary
studies, the N-peptide region did not interact
with gp120. However, it remains possible that
portions of the N-peptide region, when combined
with the DSL and C-peptide regions, may con-
tribute to the stability of the gp120–gp41 interface.
Finally, while we find a limited role for the gp120
C1 region in this study, it may stabilize the gp120–
gp41 interaction on virions via contacts with the
gp41 FP or N-peptide regions.
The trimeric Env complex is thought to be sta-
bilized primarily by gp41–gp41 interactions, since
gp120 is monomeric in solution. Ultimately,
trimeric gp120–gp41 must be studied for a full
understanding of HIV's entry mechanism. The
nature of gp41's trimerization in the prefusogenic
state is currently unknown, although experiments
with engineered disulfide bonds show that the N-
peptide region is in a conformation different from
that in the six-helix bundle.52 Recently, Pancera et
al. described a trimeric gp120 construct stabilized
by an appended C-terminal coiled-coil domain.53
Constructs of this type, combined with trimeric
versions of gp41 fragments such as DSL49, may
prove useful for structural characterization of the
trimeric gp120–gp41 interface. The relatively mod-
est (low micromolar) affinities observed here in
the monomeric gp120–gp41 interface are also
likely to be much stronger in the context of the
trimeric Env complex due to avidity effects.
Fig. 7. Revised model of HIVentry. Based on the results of this study, we propose this altered model of HIVentry. CD4
binding induces formation of the prehairpin intermediate, in which the N-trimer region is exposed and the FP is
embedded in the target cell membrane. In this intermediate, the DSL and C-peptide regions of gp41 interact with gp120,
preventing association with the N-trimer region. Coreceptor binding to gp120 triggers conformational changes that
weaken the gp120–gp41 interface. The liberated C-peptide region can then interact with the N-trimer region to form the
trimer-of-hairpins structure, leading to membrane fusion and viral entry.
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The biochemical system we describe here for
mimicking the gp120–gp41 interaction will likely
find wide utility in future structural andmechanistic
studies of the gp120–gp41 interface. Future studies
will focus on using this system to learn how
conformational changes of the gp120–gp41 interface
caused by CD4/coreceptor binding enable gp41 to
convert from its inactive prefusogenic conformation
to the postfusogenic six-helix bundle. This system
will also allow more detailed studies of the
contributions of specific residues in gp120 and
gp41 to formation of the interface, free of confound-
ing in vivo issues such as folding, trafficking, and
processing. A better understanding of this interface
is likely to aid efforts to discover neutralizing
antibodies and novel entry inhibitors that inactivate
HIV's fusion machinery by promoting premature
dissociation of the gp120–gp41 interface or, con-
versely, by stabilizing this interface to prevent gp120
dissociation.
Materials and Methods
Protein expression and purification
gp41 sequences were obtained from pEBB-JRFL. All
gp41-derived sequences contain a C-terminal His6 tag.
C43 was produced from N-C43, constructed as previously
described.10 Briefly, N-C43 was constructed by linking
C43 with its corresponding N-peptide sequences (N38,
residues 540–577) via a GGRGGS linker to form a stable
six-helix bundle (trimer of N-linker-C). N-C43 was
digested by trypsin, followed by reverse-phase HPLC
(RP-HPLC) (C18; Vydac) purification. DSL49, DSL20, C49,
DSL49ss, DSL20ss, Δ13-DSL20, L20, C20, and DSL were
expressed as C-terminal fusions to MBP linked by the TEV
protease recognition sequence, ENLYFQG. All constructs
were cloned into pET-17b (Novagen). Proteins were
overexpressed in BL21-Gold(DE3) or BL21-Gold(DE3)-
pLysS (Stratagene) and purified by Ni+-affinity column
(His-Select HC nickel affinity gel; Sigma). Purified MBP-
fused proteins were digested by TEV protease (kindly
provided by C. Hill, University of Utah) in 50 mM Tris
(pH 8.0), 0.5 mM ethylenediaminetetraacetic acid, and
0.5 mM DTT overnight at 4 °C. RP-HPLC was performed
using a C18 column (Vydac) for further purification of
gp41 fragments.
The DSL region has an intramolecular disulfide bond.
Although the two Cys residues in the DSL region are close
enough to potentially form intermolecular disulfide bonds
in the gp41 trimer,8,54,55 we exclusively produced the
intramolecular disulfide bond. This configuration is
currently thought to exist in the native gp41 structure
because it is immunologically active,47 and intermolecular
disulfide bonds have been shown to disrupt Env
proteolytic processing.48
For DSL-containing fragments, disulfide bond forma-
tion was carried out in 50 mM Tris (pH 8), 2%
Dimethyl Sulfoxide, and 3–6 M guanidine hydrochlor-
ide. DSL-containing fragments with an intramolecular
disulfide bond were separated and purified by RP-
HPLC (Supplementary Data). All gp41 fragments were
lyophilized after HPLC purification and reconstituted in
0.1% Trifluoroacetic acid to obtain high-concentration
stock solutions. 5-Helix was expressed, purified, and
prepared as described previously.10 All purified gp41
fragments were confirmed by SDS-PAGE and mass
spectrometry University of Utah Mass Spectrometry
Core Facility) and were soluble at 2 μM in phosphate-
buffered saline (PBS).
V1jns expression plasmids containing JRFL codon-
optimized gp120, ΔV3-gp120, and ΔV1/V2/V3-gp120
were gifts from X. Liang (Merck Research Laboratories).
For ΔC1 and ΔC5, nucleotides corresponding to residues
K33-Q82 were replaced with a BamHI restriction site
encoding Gly-Ser, and a stop codon was added prior to
P493 using the XbaI site in V1jns-JRFL-gp120 plasmid,
respectively. In each deletion construct, the following
regions were removed from JRFL gp120:ΔC1, K33 to Q82;
ΔC5, P493 to C-terminus; ΔV1/V2, T128 to I194; ΔV3,
T303 to I323 (Fig. 1c). All gp120 proteins were expressed in
293T-EBNA cells (Invitrogen) by transient transfection
with FuGENE 6 (Roche). Starting 24 h posttransfection,
supernatant was harvested each day for 3 days, clarified
through a 0.22-μm filter, and concentrated with a 10-kDa
cutoff Centricon (Millipore), if necessary. wt JRFL-gp120
was purified using a Lentil Lectin column (Amersham
Biosciences) as described in the manufacturer's instruc-
tions and concentrated with a 10-kDa cutoff Centricon.
Approximate gp120 concentration was measured by
Western blot analysis using commercial YU2-gp120
(ImmunoDiagnostics, Inc.) as standard.
MBP and MBP-C1/C5 were constructed into pET-17b.
C1 (residues 31–94) and C5 (residues 482–511) sequences
derived from pEBB-JRFL were linked by SGGGSGGGS.
The N-terminus of C1 was fused to MBP linked by a TEV
cleavage site (ENLYFQGS) and C9 tag (TETSQVAPA). For
the MBP control protein, a TEV cleavage sequence was
added at the C-terminus. MBP and MBP-C1/C5 were
expressed in BL21-Gold(DE3)-pLysS and purified by
amylose column (New England BioLaboratories).
The two-domain sCD4 expression plasmid, pET-9a
CD4-D1D2, was kindly provided by Raghavan Vardarajan
(Indian Institute of Science). CD4-D1D2-H6 (sCD4-H6)
was expressed in BL21-DE3-pLysS and purified by Ni+-
affinity column in 6 M guanidine hydrochloride. Purified
sCD4-H6 was refolded by dialysis into PBS (pH 7.4).
Binding assay
gp120 (~100 nM) and gp41 (2 μM) fragments were
mixed for 2 h at 23 °C in DMEM (Gibco) supplemented
with 10% fetal calf serum (Gibco). sCD4 [400 nM; National
Institutes of Health (NIH) AIDS Research and Reference
Program, contributed by Pharmacia] was added to the
mixture, as indicated. As a positive control, 2 μMsCD4-H6
was used to measure the total amount of active gp120 in
this assay. Next, 15 μl of Talon Dynabeads (binding to the
C-terminal His6 tag present in all gp41 fragments and
sCD4-H6; Dynal) was added and incubated for 15 min at
room temperature (RT). Beads were then magnetically
precipitated and washed twice with 500 μl of PBS
containing 0.01% Tween-20 and 10 mM imidazole.
Bound proteins were eluted with 400 mM imidazole and
analyzed by nonreducing SDS-PAGE (NuPAGE; Invitro-
gen) and Western blot analysis with sheep anti-gp120
serum (NIH AIDS Research and Reference Program,
contributed by Michael Phelan). JRFL-gp120 showed
broad smearing in Western blot analysis due to variable
glycosylation. To sharpen these bands for quantification,
eluted gp120 was deglycosylated by PNGaseF (NEB)
following the manufacturer's instructions. Western blot
analysis of expressed gp120 showed the expected
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monomer, but also dimers and trimers linked by
intermolecular disulfide bonds that can be broken under
mild reducing conditions, as previously reported.56 These
oligomers are easily detected byWestern blot analysis, but
are barely detectable using direct protein staining. Since
these dimers and trimers do not have completely native
conformations (due to shuffled disulfide bonds), only the
binding of monomeric gp120 was measured in this study
using nonreducing SDS-PAGE. Bands were quantified
using the OdysseyWestern Blot Imaging System (LI-COR)
with the included software. MBP (10 μM) and MBP-C1/
C5 were mixed with 2 μMDSL49 or ubiquitin H6 (Ub-H6)
in PBS containing 10% fetal bovine serum. Ub-H6 used as
a negative control was prepared as previously
described.57 To see the effect of the formation of the
trimer-of-hairpins, 3 μM 5-helix was preincubated with
DSL49 as indicated (Fig. 3a). The mixture was precipitated
and washed as described above. Bound proteins were
analyzed by nonreducing SDS-PAGE and Coomassie blue
staining.
Crosslinking
gp120 purified by Lectin Lentil column (GE Healthcare)
was dialyzed into PBS (Gibco). gp120 (0.9 μg) was mixed
with 0.25 μg of sCD4, 0.28 μg of DSL49, and/or 0.5 μg of
5-helix in 10 μl of PBS at RT. Glutaraldehyde (10 mM;
Fisher) was added and incubated for 5 min at RT, followed
by quenching with Tris. Crosslinked mixtures were ana-
lyzed by SDS-PAGE and Krypton infrared protein staining
(Pierce).
Modification of cysteines in DSL49
DSL49 was completely reduced by boiling in 100 mM
DTTand PBS (pH 7.4). Reduced cysteines were blocked by
reaction with 50 mM NEM (Sigma) or 50 mM Ac (Sigma)
in PBS or Tris-buffered saline (pH 7.4), respectively, for 1 h
at RT. Unreacted NEM or Ac was removed by ultrafiltra-
tion (Centricon; Millipore).
Cell-binding assay
HOS-pBABE-puro cells were obtained from the NIH
AIDS Reagent Program (N. Landau) and propagated in
DMEM supplemented with 10% fetal calf serum and 1 μg/
ml puromycin. Cells were dissociated using cell dissocia-
tion buffer (Invitrogen), washed and resuspended with
PBS containing 0.1% sodium azide, and incubated for
30 min at RT to prevent endocytosis.58 Cells (2.5×105)
were incubated with 2 μM gp41 fragments for 1 h at RT
and washed three times with 500 μl of PBS containing
0.01% Tween. Cells were resuspended with SDS loading
buffer and completely lysed by sonication and boiling.
Bound gp41 fragments were analyzed by SDS-PAGE and
Western blot analysis using anti-His tag polyclonal anti-
body (Abcam).
Immunostaining
DSL49 (2 μM) or DSL49ss (2 μM) was incubated with
5×106 HOS-pBABE-puro cells in the presence of 0.1%
sodium azide to block endocytosis and 5% fetal bovine
serum as blocking solution for 2 h at RT. Cells were
washed three times with 500 μl of PBS containing 0.01%
Tween (PBS-T). Cells were fixed by 4% PFA (Electron
Microscopy Sciences) in PBS for 15 min at RT, followed by
three washes with 500 μl of PBS. After blocking with 5%
goat serum (Invitrogen) in PBS for 1 h at RT, cells were
incubated with 250 μl of rabbit anti-His6 antibody
(Abcam) at 1:200 dilution in blocking solution containing
0.01% Tween overnight at 4 °C. Unbound antibody was
removed by three washes with PBS-T (10 min each at RT).
Cells were incubated with Alexa Fluor 568 goat anti-
rabbit antibody (Molecular Probes) at 1:500 dilution in
blocking solution containing 0.01% Tween for 1 h at RT,
followed by three washes with PBS-T (20 min each at RT).
Cells were placed on the slide with VectaShield (Vector
Laboratories) and photographed at magnifications of 40×
and 100×.
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EXTRACELLULAR STABILITY OF HIV-1 ENTRY 
 


















Human immunodeficiency virus type 1 (HIV-1) assembles as an immature particle and 
undergoes a maturation process after budding out of infected cells (2). In the immature 
state, Gag, HIV-1’s major structural protein, polymerizes underneath the lipid membrane 
to form a thick protein shell. During maturation, HIV-1 protease (PR) cleaves Gag into 
several products: MA remains associated with viral membrane to form the matrix layer, 
which is much thinner than the immature Gag shell; CA condenses to form a conical 
capsid core housing the NC-viral RNA genome complex; nonstructural spacer peptides, 
p1 and p2; and a C-terminal p6 peptide thought to interact with host machinery to 
facilitate viral release. Maturation is required for HIV-1 infectivity.  
HIV-1’s entry into target cells is mediated by its envelope (Env) protein subunits, 
gp41 and gp120. gp41 and gp120 form a trimeric complex, in which gp120 interacts with 
gp41 noncovalently outside the viral membrane. While gp120 mainly functions to 
recognize target cells and trigger viral entry, gp41 provides the driving force for 
membrane fusion (4). To initiate viral entry, gp120 first recognizes and binds with target 
cell receptor, CD4. This binding induces conformational change on gp120 and allows its 
further interaction with cellular coreceptor (CXCR4 or CCR5) (4). CD4 binding induces 
conformational changes not only in gp120, but also in gp41. In the native state, the gp41 
N-peptide region is not accessible for exogenous C-peptides. After CD4 binding, the N-
peptide region forms a trimeric coiled coil (N-trimer) that is accessible to exogenous C-
peptides until the endogenous C-peptide region binds to the N-trimer to form a six-helix 
bundle, which brings viral and cell membranes together for fusion (5). While the Env 
ectodomain is critical to mediate viral entry, HIV-1 together with all other lentiviruses 
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has a very long cytoplasmic tail (CT) domain (~150 aa) compared to other retroviruses 
(~20-30 aa) (2). CT interacts with the Gag MA domain, which is important for Env 
incorporation into virions (6). Furthermore, CT has the ability to affect the conformation 
of the Env ectodomain. CT truncation induces exposure of some conserved epitope 
regions on gp120, (“inside-out” signaling) (7-9). Several groups including ours have 
reported that the entry activity of mature HIV-1 is ~10-fold higher than that of immature 
viruses, and deletion of CT restores immature entry activity to the mature level (1, 10, 11). 
All these results suggest that CT functions as a bridge for internal viral components to 
regulate viral entry.   
After budding out of infected cells, virions are transmitted in the extracellular 
environment until entry into the next target cell. Viral infectivity rapidly decays outside 
of cells. However, little is known about the determinants of the viral infectivity durability 
in the extracellular environment. We are especially interested in viral entry, and thus in 
this study we focused on the extracellular stability of viral entry activity. We discover 
here that the entry activity of immature HIV-1 is much more stable than that of mature 
virions, and deletion of CT in immature virions abolishes this difference. Further 
investigation of CT and Gag reveals that both the C-terminal CT region and Gag integrity 
are important for preserving viral entry activity. Preliminary mechanistic studies show 
that neither gp120 shedding nor loss of CD4 binding accounts for this stability difference 
between immature and mature HIV-1. Little is known about viral activity changes during 




Materials and Methods 
Plasmids 
Plasmids were obtained or constructed as follows: ∆Env HIV-1 genome containing an 
inactivating integrase mutant (DHIV3-GFP-D116G (12), provided by V. Planelles), HIV-
1 wild type (WT) Env expression vector (pEBB-HXB2 (13), provided by B. Chen), 
vector expressing Vpr--lactamase (BlaM-Vpr) fusion protein (pMM310 (1)), Env 
expressing plasmid for JRFL strain (pCAGGS-JRFL-Env WT and ∆CT, provided by Dr. 
J. Binley), and partial maturation Gag mutants (provided by C. Aiken (1)). Immature 
particles were generated by cloning Gag with all PR cleavage sites mutated (pNL-MA/p6, 
provided by C. Aiken (1)) into the ∆Env Int− HIV-1 genome, while mature particles were 
produced using a ∆Env Int− HIV-1 genome with wild-type (WT) cleavage sites. ∆CT 
HXB2 Env (∆147 (14)) was provided by E. Hunter and cloned into pEBB-HXB2. CT 
truncation mutants were obtained from C. Aiken (3). Construction of GFP-TM1 was 
described in Chapter 3. 
Viral preparation and analysis 
Pseudovirion particles were produced by cotransfection of 293T cells with ∆Env int- 
HIV-1 genome, an Env-expressing vector and pMM310. For example, to generate 
immature or mature WT virus, 2.5 g of total DNA (1.23 g genome vector, 0.819 g 
WT Env expressing vector and 0.45 g pMM310) was transfected into ~1 X 106 cells 
using 10 g polyethylenimine (PEI, Sigma). The amount of Env-expressing plasmid 
input for immature WT has been defined as 100%. Media was changed at 6 h after 
transfection to avoid PEI’s toxicity. Supernatants containing secreted viral particles were 
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collected 30 h posttransfection and filtered through 0.2 m Acrodisc syringe filters (Pall). 
A series of viruses prepared on the same day is defined as one batch of viruses. 
For western blot (WB) analysis of viral concentration and Env incorporation level, 
virus supernatants were purified by centrifugation through a sucrose cushion (20% 
sucrose in 1 X TNE buffer: 0.1 M NaCl, 1 mM EDTA, 10 mM Tris, pH 7.6) at 20,000 X 
g for 90 min at 4°C. The pellet was resuspended in SDS-PAGE reducing sample buffer 
and resolved by SDS-PAGE. WB was developed using rabbit polyclonal anti-CA 
(provided by W. Sundquist), mouse monoclonal anti-gp41 Chessie 8 antibody 
(supernatant from Chessie 8 hybridoma provided by NIH AIDS Research and Reference 
Reagent Program, ARRRP), sheep polyclonal anti-gp120 (contributed by M. Phelan, 
ARRRP) and rabbit polyclonal anti-BlaM (Chemicon/Millpore). Blots were quantiﬁed 
using Li-Cor’s Odyssey scanner.  
Viral entry assay 
The viral entry assay was performed as described (11). Briefly, HIV-1 particles mixed 
with DEAE-Dextran (4 g/ml) were added onto HOS-CD4-CXCR4 cells (provided by 
B.Chen), followed by centrifugation at 1,800 X g for 30 min at 4°C and incubation at 
37°C for 2 h. After removal of unbound viruses, 1 M CCF2-AM solution (-lactamase 
substrate, Invitrogen) was incubated with cells at 13°C for 17 h. Uncleaved and cleaved 
CCF2-AM have emission peaks of 520 nm (green) and 447 nm (blue), respectively, 
under 409 nm excitation. Fluorescent signals from both channels were detected using an 
Olympus MVX10 fluorescent microscope and quantified using ImageJ software (NIH). 




The coprecipitation assay was done as described previously (15). Briefly, viruses with 
or without preheat were incubated at 37°C for 1 h with His6 tagged CD4 (at a final 
concentration of 300 ng/l) in DMEM (Gibco) supplemented with 10% fetal calf serum 
(Gibco). Then 15 l of Talon Dynabeads (Ni magnetic beads; Dynal) was added to the 
solution and incubated for 15 min at room temperature with gentle tapping every 3 min. 
Beads were then magnetically precipitated and washed twice with 500 l of PBS 
containing 0.01% Tween-20 and 10 mM imidazole. Bound viruses were eluted with 400 
mM imidazole and dissolved by reducing SDS-PAGE (NuPAGE; Invitrogen).  
Results 
Immature HIV-1 entry is more stable than that of mature virions 
To examine the durability of virions in the extracellular environment, we focused on 
viral entry activity. At 4°C, viral entry activity is well preserved. Therefore, the ratio of 
the entry activities after incubation at 37°C vs. 4°C is defined as the extracellular stability 
of viral entry activity. After 24 h incubation at 37°C, the entry activity of mature HIV-1 
(HXB2 strain, CXCR4-tropic) drops to ~10% of those incubated at 4°C (Fig. B-1 A). In 
contrast, immature HIV-1 maintains ~50% entry activity. For experimental convenience, 
we increased incubation temperature to 50°C, in order to accelerate the decay process 
(Fig. B-1 A). After 1 h incubation at 50°C, mature HIV-1 retains only ~20% entry 
activity, while immature virions maintain ~80-90% entry activity. 50°C treatment does 
not change the relative relationship between immature and mature extracellular stability. 
Therefore, for all the following experiments, we used 1 h incubation at 50°C vs 4°C as 
our standard experimental condition.  
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Determinants for extracellular stability in immature state 
Maturation causes a dramatic increase in viral entry activity, which is dependent on 
CT (1, 10, 11). Therefore, we investigated whether CT is important for extracellular 
stability of viral entry activity. Deletion of CT dramatically decreases the stability of 
immature viruses to below the mature level (Fig. B-1 A). As a control, mature ∆CT is as 
unstable as mature WT, suggesting CT only functions to preserve viral entry activity in 
immature state (Fig. B-1 A). To see whether this is general for HIV-1 strains, we tested 
JRFL, a primary CCR5-tropic strain, and found a similar result (Fig. B-1 B).  Further 
mapping of CT showed that deletion of 28 or more residues from the C-terminus of CT 
disrupts stability of immature HIV-1 entry (Fig. B-2).  
PR cleavage of Gag induces the dramatic morphological change during HIV-1 
maturation. Therefore, we employed a series of Gag mutants with one or more PR 
cleavage sites mutated, to investigate the importance of Gag integrity for extracellular 
stability. These Gag mutants were coexpressed with HIV-1 WT Env (HXB2 strain) and 
their extracellular stability was measured as above. Any PR cleavage between MA and 
NC greatly reduces the entry activity stability of immature viruses (Fig. B-3). In contrast, 
PR cleavage only between NC and p6 has a much milder effect, making the viruses ~50% 
stable as immature WT.  
We previously defined particle stiffness as a novel regulatory level for viral entry. 
During maturation, HIV-1 particles are dramatically softened, contributing to increased 
viral entry activity. In Chapter 3, we showed that coexpression of a transmembrane 
anchored CT domain (GFP-TM1) increases particle stiffness of ∆CT immature virions in 
a dose-dependent manner. However, this coexpression of GFP-TM1 on an immature 
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virion does not preserve viral entry activity (supplemental Fig. B-1), suggesting that the 
loss of extracellular stability with CT deletion is not due to lowered particle stiffness.  
Neither gp120 shedding nor loss of CD4 binding accounts for  
the loss of viral entry activity 
Although important for viral entry, gp120 is tethered to viral surface by its non-
covalent interaction with gp41. Therefore, it is possible that long incubation causes the 
shedding of gp120. However, the gp120 incorporation level is similar between 4°C and 
50°C treated immature ∆CT viruses, arguing against a role for shedding (Fig. B-4).  
Binding with CD4 is an early critical step for viral entry. Therefore, we further looked 
into whether deletion of CT causes a loss of Env’s CD4 binding ability over time. A His-
tagged CD4 (CD4-H6) was used to coprecipitate viruses with Env capable of CD4-
binding. No significant difference was found between 4°C and 50°C treated immature 
∆CT or WT (Fig. B-5), suggesting that loss of CD4 binding ability is not the reason that 
CT truncation destabilizes viral entry activity.  
Discussion 
Although the detailed time window is yet defined, HIV-1 needs to survive in the 
extracellular environment to enter the next target cell within the same or from different 
hosts. Mature HIV-1 loses its infectivity within hours in tissue culture medium, but little 
is known which biological activity accounts for this loss. An interesting question is 
whether maturation has an effect on viral durability during transmission. In this study, we 
focused on viral entry activity and found that immature HIV-1 preserves its entry activity 
much better than mature virions. Both CT’s C-terminus and Gag integrity were shown to 
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be important for preservation of viral entry activity, but neither gp120 association with 
virions nor CD4 binding ability is affected by CT deletion.  
In Chapter 3, we showed that the low viral entry activity of immature HIV-1 is partly 
due to the high particle stiffness. Therefore, we speculated that stiff particles in the 
immature state may function to preserve the viral entry activity in the extracellular 
environment. However, coexpression of GFP-TM1 with immature ∆CT, which was 
shown to stiffen the whole particle, failed to preserve the viral entry activity after 50°C 
treatment (data not shown). Since GFP-TM1 greatly impairs ∆CT incorporation (Chapter 
3), we coexpressed GFP-TM1 with an unrelated viral Env (VSVg). While GFP-TM1 still 
stiffens the immature virions and does not affect VSVg incorporation, coexpression with 
GFP-TM1 does not recover the entry activity of immature VSVg from unmeasurable 
level. This result suggests that stiffening the viral particle cannot preserve the 
extracellular stability of viral entry. The underlying mechanism that maturation lowers 














Fig B-1. Extracellular stability of HIV-1 strains.  
(A). Extracellular stability of HXB2 strain at 50°C or 37°C.  Extracellular stability 
values at y-axis are calculated as relative viral entry activities of viruses after 
incubation at 50°C for 1 h or at 37°C for 24 h, compared to viral entry activity 
measured in particles incubated for the same time at 4°C.  
(B). Extracellular stability of JRFL strain. Relative extracellular stability at y-axis 
is calculated as relative viral entry activity of viruses after incubation at 50°C for 1 
h compared to those incubated at 4°C for 1 h, and then normalized to that of 
immature ∆CT.  







Fig B-2. Important CT regions for extracellular stability.  
(A). CT truncation and point mutants. Truncation mutants are named after the 
number of residues removed from C-terminus of CT. In LER851AAA, three 
residues (L851E852R853, HXB2 numbering) are replaced by Ala. The figure is 
reprinted with permission from (3). 
(B). Extracellular stability of immature HIV-1 bearing these CT mutants. 
Extracellular stability values at y-axis are calculated as relative viral entry activity 
of viruses incubated at 50°C for 1 h compared to those at 4°C for 1 h.  





Fig B-3. Gag integrity is important for extracellular stability.  
(A). Partial maturation Gag mutants. Red crossing represents that the PR cleavage 
site at that location has been mutated. The figure is reprinted with permission from 
(1).  
(B). Extracellular stability of Gag mutants bearing WT HIV-1 Env. Y-axis values 
are calculated as relative viral entry activity of viruses incubated at 50°C vs. 4°C 
(for 1 h).  














Fig B-4. Loss of stability is not due to disruption of virions or gp120 shedding.  
Immature ∆CT or WT viruses were incubated at 50°C or 4°C for 1 h, followed by 
sucrose cushion purification and WB to analyze their Gag and gp120 
concentrations. After sucrose purification, only intact viral particles are 
concentrated (represented by Gag concentration). Therefore, virion integrity at 
50°C (y-axis, left) is represented by relative Gag concentration of 50°C treated 
viruses (purified by sucrose cushion) to those incubated at 4°C. Virion integrity of 
immature ∆CT incubated at 4°C is less than 2 fold higher than that incubated at 
50°C, suggesting that the majority of immature ∆CT viruses remain intact after 
50°C treatment. 
Similarly, if gp120 sheds from viral particles, it will not be concentrated by 
sucrose cushion together with intact viral particles. The gp120 shedding at 50°C is 
represented by relative gp120 concentration (y-axis, right) of 50°C treated viruses 
(purified by sucrose cushion) to those incubated at 4°C. The gp120 concentration 
of intact immature ∆CT incubated at 50°C is similar to that incubated at 4°C, 
suggesting that gp120 does not shed from virions after 50°C treatment. 

































Fig B-5. Disruption of stability is not due to loss of Env’s CD4 binding ability. 
Immature ∆CT or WT viruses were incubated under the condition listed above 
before going through coprecipitation assay with CD4-H6 (His tagged CD4). WB 
was developed using anti-CA (red, detect Gag), anti-His (red, detect CD4-H6) and 
anti-CT (green, detect WT Env) antibodies. The same amount of each virus was 
added to WB as loading controls (lane 1 and 4). Based on molecular weight, the 
bottom red bands represent CD4-H6, and the middle red bands represent Gag. 
Comparison of Gag signal between lane 2 and 3 (or between lane 5 and 6) shows 
that CD4-H6 can pull down similar amount of ∆CT virions (or WT virions) under 
either condition, suggesting that ∆CT Env’s ability of CD4 binding does not 
change even after 50°C incubation. Therefore, loss of extracellular stability for 
immature ∆CT viruses after 50°C incubation is not due to loss of Env’s ability to 
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Supplemental Fig B-1. GFP-TM1 does not rescue the extracellular 
stability of immature ∆CT. 
Immature virions bearing both ∆CT and GFP-TM1 were produced as 
described in Chapter 3. 100% means that the amount of GFP-TM1 plasmid 
used in transfection is equal to that of ∆CT. Extracellular stability of the 
above viruses was calculated as relative entry activity of viruses after 50°C 1 
h treatment compared to that of 4°C treated. Relative extracellular stability at 
y-axis was obtained by normalizing the extracellular stability value of each 
virus to that of immature ∆CT.  
Error bars indicate the SEM. 
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